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Tubulin-binding dibenz[c,e]oxepines:  Part 2.
1    
Structural variation and biological 
evaluation as tumour vasculature disrupting agents 
Steven B. Rossington,
 
John A. Hadfield,
 
Steven D. Shnyder,
 
Timothy W. Wallaceand Kaye J. 
Williams 
 
 
5,7-Dihydro-3,9,10,11-tetramethoxybenz[c,e]oxepin-4-ol 1, prepared from a dibenzyl ether precursor via Pd-catalysed intramolecular direct 
arylation, possesses broad-spectrum in vitro cytotoxicity towards various tumour cell lines, and induces vascular shutdown, necrosis and 
growth delay in tumour xenografts in mice at sub-toxic doses. The biological properties of 1 and related compounds can be attributed to their 
ability to inhibit microtubule assembly at the micromolar level, by binding reversibly to the same site of the tubulin -heterodimer as 
colchicine 2 and the allocolchinol, N-acetylcolchinol 4. 
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1. Introduction 
 
As the conduit for oxygen, nutrients and waste products, the 
vascular system that supports a tumour is a rational target for 
anticancer therapy.  Two strategies have emerged for the clinical 
exploitation  of  this  principle,
2    
the  first  being  the  use  of 
angiogenesis inhibitors, which target growth factors so as to 
prevent the formation of new vasculature.
3 
The pioneering 
example   of   this   approach   is   the   monoclonal   antibody 
bevacizumab (Avastin).
4 
The second strategy is to employ 
vascular disrupting agents (VDAs) to attack newly-formed 
tumour vasculature, which is structurally flawed by excessive 
branching, uneven diameter, shunts, etc., and more sensitive than 
normal host vasculature to small molecules that perturb the 
morphology and functionality (migration, adhesion, proliferation) 
of the nascent endothelial cells.
5   
Microtubules play a prominent 
role in maintaining the physical structure of these cells, and most 
VDAs are tubulin-binding agents that undermine tubulin- 
microtubule dynamics at sub-micromolar concentrations. 
In seeking new structures for screening as VDAs, we 
identified the dibenz[c,e]oxepinol 1 as a potent inhibitor of 
microtubule assembly and a possible lead in this context.
1     
A 
crystallographic analysis of the dibenz[c,e]oxepine nucleus
6 
led 
by virtue of its ability to match, in both degree and sense, the 
conformational helicity of colchicine 2, which is crucial to the 
latter's  ability  to  bind  to  tubulin,
7   
and  by  analogy  with  N- 
acetylcolchinol methyl ether (NCME) 3, whose binding to 
tubulin is strong but rapidly reversible, i.e. compatible with drug- 
like   pharmacokinetics.
8 
Indeed the parent phenol N- 
acetylcolchinol (NAC) 4 was developed as a VDA in the form of 
the phosphate prodrug ZD6126 5, although the project was 
curtailed following the observation of adverse cardiac events in 
phase I clinical trials.
9,10     
Various alternative  structures have 
progressed to clinical trials as VDAs,
11  
the best known being 
combretastatin A-4 (CA-4) 6 which, as the phosphate prodrug 7 
(CA-4P; fosbretabulin; Zybrestat), has featured in human trials as 
a single agent
12 
and in combinations with cytotoxic agents 
(paclitaxel, carboplatin), radiotherapy, or the antiangiogenic 
agent, bevacizumab.
13 
Other stilbenes in development include 
combretastatin A-1 (CA-1) 8, in the form of the prodrug 9 
(OXi4503),
14 
and AVE8062 10 (ombrabulin).
15   
The benzofuran 
11 (BNC105),
16 
the diketopiperazine 12 (plinabulin),
17 
the 
pyrimidine 13
18 
and the chromene 14 (crolibulin)
19 
have also 
progressed to clinical trials.  Despite their structural diversity, all 
of these candidate VDAs bind to tubulin at, or close to, the same 
site as colchicine 2, which is located at the interface of the two 
20 
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subunits of the ,-tubulin heterodimer.
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While the colchicine binding site of tubulin can accommodate 
a range of structures, it is not an ideal target for therapeutics. 
Agents that inhibit microtubule assembly by binding to this site 
are  associated  with  dose-limiting  cardiac  events  (ischemia, 
infarction, ventricular tachycardia),
21 
and this has been attributed 
 
2. Results and discussion 
 
2.1. Synthesis of materials 
 
Our  original  route  to  the  key  structure  1,  based  on  a 
1 
to cell-cycle arrest in the endothelial cells of the myocardium.
22
 conventional  Ullmann  biaryl  synthesis, was   improved   by 
Zybrestat 7 shows neurotoxic and cardiac effects (prolonged QT 
interval), and clinical trial protocols include measures to 
counteract hypertension and cardiac ischemia.
13a,23     
Prolonged 
switching to iodoarene cross-coupling partners (Scheme 1).  The 
C-ring  precursor  23  was  conveniently  prepared  by  direct 
iodination of o-vanillin mesylate 22 using iodine and periodic 
27 
QT interval is also observed with OXi4503 9
14  
and CYT997 acid, and the same method provided the A-ring precursor 24 
13.
18a 
Cardiotoxicity is thus a generic issue with tubulin- 
targeting VDAs, highlighting the need for finely-balanced 
therapeutics that are not compromised by this problem.
24
 
from   3,4,5-trimethoxybenzaldehyde.      The   outcome   of   the 
Ullmann coupling of 23 and 24 was strongly dependent on the 
reaction conditions, but guided by the painstaking analysis of this 
type  of  reaction  by  Brown  and  coworkers,
28    
we  obtained 
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acceptable yields of 25 using a solvent-free 3:1 mixture of the 
two components, a 5-fold excess of Cu powder, and careful 
control of the reaction time and temperature. Ring-closure of the 
diol 26 to 27 was induced with aq. HBr, and the methanesulfonyl 
protecting group was cleanly removed from 27, to give 1, using a 
modified version of Carreira's method.
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The dibenz[c,e]oxepine pharmacophore is easily accessible
1,25 
and potentially tunable with respect to binding, metabolic and 
transport characteristics.
26   
In this paper we describe new routes 
to the lead structure 1 and its biological evaluation as a VDA, 
along with the analogues 15–20.  The results show that in human 
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tumour xenografts in mice, the prodrugs 15 (derived from 1) and 
21 (from the clinically tested VDA 5) are similar in their ability 
to induce necrosis, and that 1 inhibits tumour growth in vivo. 
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Scheme 1. Improved Ullmann cross-coupling route to 1. 
 
We also developed a potentially more versatile approach to 1 
featuring a Pd-catalysed intramolecular direct arylation (IDA) 
reaction as the cyclisation step.   This strategy called for the 
construction of a dibenzyl ether bearing the latent A- and C-ring 
substituents of the target compound, together with a single 
halogen atom to mediate the metalation step. To prepare such a 
precursor for 1, the MOM-protected aldehyde 29 was reduced to 
the alcohol 30, which was then alkylated using 3,4,5- 
trimethoxybenzyl bromide 31 (Scheme 2). The resulting ether 32 
was subjected to the IDA cyclisation conditions first described by 
Fagnou and coworkers
30,31 
and adapted by us for the preparation 
of dibenz[c,e]azepines.
32    
Chromatography of the product gave 
the desired heterocycle 34 in moderate yield, confirming that this 
is a viable approach to dibenz[c,e]oxepines. Subsequent removal 
of the MOM group from 34 using aq. HCl completed the new 
route to the target 1. 
2.2. Biological evaluation 
2 .2 .1 .  1. Inhibi t ion  of microtubule  assembly  and  
in vi tro ant iprol i f erat ive  act ivi ty  
Dibenzoxepines were routinely screened for their ability to 
inhibit  microtubule  assembly
34,35    
and  for  growth  inhibitory 
activity (IC50) against the K562 human chronic myelogenous 
leukaemia cell line.
36   
Both of these assays are routinely used for 
evaluating test compounds and provide a useful comparison with 
benchmarks such as colchicine 2 and CA-4 6. The results (Table 
1) show that the ability of the phenolic compound 1 to inhibit 
microtubule assembly is matched by the phosphate 15 (entry 6), 
with the latter also showing sub-nanomolar IC50 values in the 
K562 assay.   The activity shown by the triflate 18 (entry 9) is 
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Table 1. Activities (IC50) of compounds in the microtubule 
assembly and K562 in vitro cytotoxicity assays. 
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Scheme 2. Intramolecular direct arylation route to 1. 
 
In seeking a water-soluble version of the dibenzoxepinol 1, we 
used a conventional reaction sequence
33 
to prepare the disodium 
phosphate 15 via the intermediates 35 and 36. Mixing the 
dihydrogen phosphate 36 with two molar equivalents of freshly 
prepared sodium methoxide in methanol, followed  by 
evaporation and drying in vacuo, provided the disodium salt 15 
as white powder.  Although essentially homogeneous by 
1
H, 
13
C 
and 
31
P NMR spectroscopy, this material proved to be 
hygroscopic, and microanalytical samples always retained small 
amounts of water and methanol. 
7 16 7.4 110 
8 17 >10 85 
9 18 15 0.25 
10 19 >10 16 
11 20 >10 10 
 
aConcentration required for 50% inhibition of tubulin assembly. 
bEntries in this column are corrected for variations in the value for 6, which 
was used as a reference for assay batches. 
cConcentration that inhibits the growth of K562 cell line by 50% after 
incubation for 5 days. Each drug concentration was tested in triplicate, and 
the standard error of each value is <10%. 
dEntries in this column are normalised to the value for 6, which varied over 
the range 1.2–3.0 between batches. 
 
MeO 
 
 
MeO 
OMe 
 
 
 
 
O 
 
O 
 
MeO 
 
 
MeO 
OMe  
 
 
 
CHO 
CHO 
eValues from ref. 1. 
fValue from ref. 37. 
gNot determined. 
 
 
OMe 
O   P   OR 
OR 
 
 
NO2 
2 .2 .2 .  2. In v itro screening  against  NCI- 60 cell  l ines  
The dibenzoxepines 1 and 15–17 were evaluated in the US 
35 R = CH2Ph 37 
36 R = H 
The dibenzoxepinol 1 was also converted into the derived 
triflate 18 by conventional means. The amine 20 was acquired in 
three steps from the biaryl dialdehyde 37, which proved 
accessible via an Ullmann cross-coupling reaction. Subsequent 
reduction and cyclisation gave the nitro compound 19, which was 
transformed into the amine 20 by catalytic hydrogenation. 
National Cancer Institute (NCI) anticancer drug screen against 
the NCI-60 panel of human tumour cell lines.
38,39 
The sixty cell 
lines of this panel are organised by disease type, and test data 
relating to both the levels and the patterns of activity across the 
panel can be instructive. Some of the results of the NCI-60 five- 
dose assay of the dibenzoxepines are shown in Table 2. 
Compounds 1 and 16 reach similar levels in their inhibitory 
effects, each with more than twenty instances in which the GI50 
value is below 100 nM, whereas 15 and 17 register this level only 
with the MDA-MB-435 (melanoma) cell line. 
 
 
NMe2 
PCy2 
 
33 
 Tubulin assembly K562 assay 
Entry Compound IC50 M
a,b
 IC50 nM
c,d
 
 
Table 2. In vitro cell growth inhibition data for various 
dibenzoxepines against the NCI-60 panel of human cancer 
cell lines. 
 
 
 
The results with the human colorectal tumour cell line HCT- 
15, which is known to express multidrug resistance protein (P- 
40 
Cell growth inhibition (GI50, µM)
a,b,c
 glycoprotein), implies that the inhibitory properties of 1 and 16 
Panel Cell line 1 15 16 17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a
GI50: concentration required for 50% cell growth inhibition. 
are not unduly affected by this efflux pump, which can 
undermine the effects of tubulin-targeting anticancer agents.
41
 
The NCI-60 mean GI50  values for 1 and 16 are similar (ca. 0.3 
µM), which compares to 0.04 µM for NCME 3. 
The NCI-60 screening results from the dibenzoxepines 1 and 
15–17, together with the public data for the colchicinoids 2–4 
and the stilbenes 6 and 7, were analysed using the matrix 
COMPARE algorithm.
42     
In this type of analysis, the activity 
profile of a 'seed' compound against the NCI-60 cell lines can be 
compared to that of any 'target' compound in the same database, 
with the COMPARE algorithm being used to generate a series of 
correlation coefficients (Table 3). Compounds that exert their 
inhibitory effects by similar mechanisms of action can produce 
similar patterns of differential antiproliferative data, and the 
coefficients within the dibenzoxepine matrix (Table 3a) provide a 
reasonable case for the mechanistic correlation of this group of 
compounds, the borderline case being 16. However, the extent to 
which this correlation is based on interaction with tubulin 
remains unclear, as is illustrated by the second section of results 
obtained with 2–4, 6 and 7 (Table 3b). Matrix COMPARE 
coefficients   (r   values)   less   than   0.6   are   of   questionable 
significance,
43,44    
and  there  is  considerable  variation  in  the 
coefficient values across the whole matrix, ranging from notable 
homology (2 with 3; 3 with 6; 6 with 7) to almost complete 
disparity with N-acetylcolchinol 4, which in turn shows a modest 
correlation with 16. Taken together, these results provide a 
reminder that the relationship between cytotoxicity (or 
cytostaticity) and the ability to shutdown vasculature remains 
obscure. 
Using the standard COMPARE protocol, the antiproliferative 
activity profiles of 1 and 15–17 were compared with those of the 
NCI  standard  agents  collection  of  anticancer  agents.
45      
This 
analysis, which can be used to identify the cellular targets of 
44,46 
b
Only the cell-lines featuring one GI50 value below 100 nM are antitumour agents, was extended to include compounds 2–4, 
included in this table; see Supplementary Material for the full data 
set. 
6 and 7 as the seeds (Table 3c).  The observed correlation of 15 
with  maytansine  and  vincristine,  which  are  known  to  target 
47 
c
Shading is applied to values below 100 nM; ND = not determined. microtubule  formation, provides  further  evidence  that,  as 
intended, the biological target of the dibenzoxepines is tubulin. 
Leukaemia CCRF-CEM 0.04 0.29 0.08 0.35 
 HL-60(TB) 0.03 0.32 0.04 0.39 
 K-562 0.04 0.28 0.04 0.21 
 MOLT-4 0.06 0.40 0.09 0.47 
 SR 0.04 0.19 0.04 0.17 
Non-small 
cell lung 
NCI-H522 0.04 0.30 0.28 0.39 
Colon HCT-116 0.32 0.43 0.05 0.37 
HCT-15 0.08 0.44 0.08 0.48 
KM12 0.05 0.30 0.05 0.36 
SW-620 0.05 0.40 0.05 0.40 
 0.09 0.79 0.46 1.32 
 
SK-OV-3 0.07  
Renal RXF393 0.04 0.21 0.08 0.20 
Prostate DU-145 0.06 0.39 0.18 0.37 
 
CNS SF-268 
 
SF-295 0.27 0.32 0.06 0.33 
 SF-539 0.05 0.33 0.16 0.35 
 SNB-19 0.14 0.51 0.98 0.68 
 SNB-75 0.07 0.54 0.09 0.46 
 U251 0.30 0.48 0.10 0.48 
Melanoma LOXIMVI 0.08 0.66 0.21 0.87 
 M14 0.05 0.27 0.05 0.23 
 MALME-3M ND 2.51 >100 >100 
 MDA-MB-435 0.03 0.04 0.03 0.05 
 SK-MEL-2 0.26 5.37 0.10 0.56 
 SK-MEL-28 1.58 0.89 0.08 ND 
 SK-MEL-5 0.04 0.26 0.03 0.21 
 UACC-62 1.00 5.50 0.08 0.79 
Ovarian NCI/ADR-RES 0.05 0.28 0.07 0.36 
 OVCAR-3 0.21 0.28 0.05 0.25 
   0.40 0.13 0.47 
 
Breast BT-549 0.26 2.24 0.20 0.54 
 HS578T 0.04 0.24 0.24 0.43 
 MCF7 0.07 0.40 0.04 0.40 
 MDA-MB-468 0.22 1.15 0.03 0.17 
 
Table 3. Results of COMPARE analyses involving the dibenzoxepines 1 and 15–17. (a) Matrix COMPARE data for the 
dibenzoxepines. (b) Standard COMPARE data for colchicinoids 2–4 and stilbenes 6 and 7. (c) Correlations from a standard 
COMPARE analysis of dibenzoxepines with the NCI standard agent database.
a,b
 
 
 Target 
vector 
Seed vector 
1 15 16 17 2 3 4 6 7 
 
a 
1 
15 
16 
17 
 0.81 0.84 0.79  
0.81 
0.84 
0.79 
 0.66 0.73 
0.66 
0.73 
 0.86 
0.87  
 
b 
2 colchicine 
3 NCME 
4 NAC 
6 CA-4 
7 CA-4P 
0.50 0.50 0.53 0.52 0.74 0.22 0.51 0.49 
0.43 0.48 0.42 0.45 0.74 0.02 0.71 0.58 
0.44 0.33 0.62 0.45 0.22 0.02 0.01 0.12 
0.40 0.43 0.31 0.31 0.51 
0.58 0.53 0.40 0.38 0.49 
0.71 
0.58 
0.01 0.77 
0.12 0.77  
 
c 
maytansine 
vincristine 
paclitaxel 
rhizoxin 
vinblastine 
0.51 0.56 0.54 
0.53 
0.56 0.76 0.87 
0.56 0.78 0.81 
0.47 
0.41 
0.67 
0.58 
0.45 
0.50 0.57 0.62 
0.51 0.45 0.49 0.60 0.54 0.36 0.49 – – 
0.43 0.45 0.45 0.52 
0.43 0.50 0.47 0.48 
0.74 0.83 
0.75 0.89 
0.38 
0.29 
0.64 0.59 
0.64 0.44 
aMatrix (r) values are Pearson's correlation coefficients,38 based on a comparison of the NCI GI50 mean graphs for each compound; see Supplementary Material 
for full search parameters and results. 
bShading is arbitrarily applied to r values ≥0.55. NCI descriptors: 2, NSC 757; 3, NSC 51046; 4, NSC 51045; 6, 613729; 7, NSC 645646; maytansine, NSC 
153858; vincristine, NSC 67574; paclitaxel, NSC 125973; rhizoxin, NSC 332598; vinblastine, NSC 49842. 
2 .2 .3 .  3. In vivo ant ivascular  effects  of 15  
Given its close structural analogy and progress to clinical 
trials, we selected the erstwhile drug candidate 5,
9,48 
in the 
form of its disodium salt 21, as a benchmark for assessing the 
ability  of  15  to  function  as  a  VDA  at  levels  beneath  the 
maximum tolerated dose (MTD). In a side-by-side single-dose 
study, seven groups of athymic nude mice (n=3 per group) 
bearing subcutaneous DLD-1 human colon adenocarcinoma 
xenografts were used to assess the effects of treatment with the 
test compounds 15 and 21 on the functional vasculature in 
tumours. Once an established tumour vascular network was in 
place, mice were treated with a single intravenous dose (400 
mg/kg) of 15 or 21 (three groups per compound). The results 
(Figure 1) provided a clear demonstration of the vascular 
shutdown induced by both compounds, peaking ca. one hour 
after the administration of the compound. This state persisted 
throughout the 24-h study period for 21, whereas for 15 some 
recovery of vasculature was evident from 4 h post dose. 
The extent of tumour necrosis (Figure 2) was only seen to 
be different to the control at 24 hours post dose for both 
compounds, which is consistent with the time delay expected 
for necrosis to occur following loss of blood supply to the 
tumour cells. The ability of the dibenzoxepine 15 to target 
experimental tumours is clearly evident, and parallels that of 
the related allocolchinol 21. 
Representative images from the functional vasculature and 
necrosis studies are provided in Figures 3 and 4 respectively. 
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Figure 1. Chart showing the time-dependent vascular shutdown of DLD-1 human colon adenocarcinoma xenografts in mice following a single intravenous 
dose (400 mg/kg) of 15 or 21 (mean ± SEM). 
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Figure 2. Chart showing the quantification of tumour necrosis in DLD-1 human colon adenocarcinoma xenografts in mice following a single intravenous 
dose (400 mg/kg) of 15 or 21 (mean ± SD). 
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Figure 3.   Representative images of DLD-1 human colon adenocarcinoma xenografts showing remaining functional vasculature using Hoechst 33342 
staining, following a single intravenous dose of 15 or 21 at 400 mg kg–1 at 1, 4 and 24 h post dose. 
 
 
Figure 4. Representative images of haematoxylin- and eosin-stained DLD-1 human colon adenocarcinoma xenografts following a single intravenous dose of 
15 or 21 at 400 mg kg–1 at 1, 4 and 24 h post dose. 
p 
2 .2 .4 .  4. In vivo ant i tumour  effects  of 1 
The potential of the benz[c,e]oxepine series as a source of 
in vivo antitumour agents was investigated using benzoxepinol 
1 in a two-dose study with mice bearing subcutaneous Calu-6 
lung tumour xenografts.  Calu-6 is well vascularised and has 
been used previously to study VDAs.
49     
Guidelines for the 
MTDs of various dibenzoxepines in mice were obtained by 
monitoring the effects of a single exposure on body weight 
over two weeks, and a limit of 270 mg/kg was set for 1 (Figure 
5a). The antitumour properties of 1 were then monitored in a 
10-day study of mice with implanted Calu-6 xenografts. Doses 
of one-quarter or one-half of the nominal MTD on days 1 and 
5 had approximately the same inhibiting effect on tumour 
growth for 24 h, with regrowth then resuming at the original 
rate (Figure 5b). The dibenzoxepine 1 was thus demonstrated 
to be carcinostatic, inducing a growth delay in the 
experimental tumours at one-quarter of the nominal MTD, and 
was well tolerated in tumour-bearing mice. 
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Figure 5. The dibenzoxepine 1 is well tolerated in tumour-bearing mice and induces a highly significant growth delay in subcutaneous Calu-6 lung tumour 
xenografts. (a) shows average mouse weight, (b) shows average tumour volume (n=5 control, n=6 treated mice per group). Arrows indicate administration of 1 
at the noted dosages. The doses 67.5 mg/kg and 135 mg/kg equate to 0.25 and 0.5 MTD respectively. Compound 1 was dosed in 5% DMSO in peanut oil. 
M
o
u
s
e
 w
e
ig
h
t 
(g
) 
T
u
m
o
u
r 
v
o
lu
m
e
 (
m
m
3
) 
2 .2 .5 .  5. Mechanist ic  considera t ions  
The tubulin-binding capability of the dibenzoxepine 1 is 
consistent with its structural analogy with colchicine. The 1SA0 
crystal structure provides a detailed picture of the interaction of 
N-deacetyl-N-(2-mercaptoacetyl)colchicine (DAMA-colchicine) 
38 with the interchain boundary of the -tubulin heterodimer,
20
 
which accounts for the disruptive effect of colchicinoids on the 
finely-poised dynamics of this interface. We  speculate  that, 
while chemically distinct from colchicine 2 and the 
combretastatins such as 6, the dibenzoxepine 1 binds to the - 
tubulin  heterodimer  at  the  same  location  and  in  a  similar 
manner.
1    
Our mechanistic model for this interaction, shown in 
Figure 6a, assumes the favourable locations of H-bond donor and 
acceptor sites a and b that can anchor the C-ring of the -tubulin- 
bound ligand to the nearby -tubulin. It is generally assumed 
that β -Cys241 provides colchicinoids with the third anchor c, 
although the case for this being solely through H-bonding is less 
compelling, as the trimethoxy motif is not indispensible.
50
 
hydroxy group can function as an H-bond donor in the domain 
normally occupied by the amide NH of the colchicinoid. 
 
  
(a) (b) (c) 
 
Figure 7. Calculated and crystallographic models overlaid on atoms 
C(11A), C(8) and C(10) of 1. (a) The dynamic 3D-structure of 1 in aqueous 
solution. Carbon atoms are shown in grey and oxygen in red. (b) The bound 
conformation of 38 from 1SA0 (residue 701, carbon atoms in grey) and the 
closest matching preferred solution conformer of 1 (carbon atoms in green) 
aligned in the same pose. (c) The crystal structure of 3 (carbon atoms in 
grey) with the closest matching solution conformer of 1 (carbon atoms in 
(a) -CYS241 
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green) and model of 6 (carbon atoms in pink) aligned in the same pose. N 
atoms are shown in blue and O in red; H are omitted for clarity. 
 
The mechanistic model represented in Figure 6 should extend 
to the amine 39, which also bears a C(4)-substituent suited to the 
role of the H-bond donor in anchor a, capable of binding to the 
residue Thr179 located on the -tubulin chain (Figure 6b). On 
the same basis, and by analogy with ombrabulin 10, we speculate 
that a range of amides 40 derived from 39 may be potent tubulin 
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accessibility and biological properties of a series of substituted 
dibenz[c,e]oxepines, identifying candidate compounds by their 
ability to inhibit the growth of experimental tumour cell lines in 
vitro. The most potent of the compounds studied was the 
benzoxepinol 1, which in the NCI-60 anticancer  drug screen 
manifested broad-spectrum antiproliferative activity whose 
profile (COMPARE analysis) indicated tubulin as the biological 
target. The results of in vivo studies confirm that the disodium 
phosphate prodrug 15, derived from 1, induces vascular 
shutdown and necrosis in DLD-1 human colon adenocarcinoma 
OMe a 
b 
 
 
 
Figure 6. Depictions of (a) the supposed binding interactions within (or 
leading to) the DAMA-colchicine:-tubulin:RB3 (1SA0) crystal structure 
(ref. 24a) and (b) the proposed analogy of 1 and 39. 
 
Conformational analysis of 1 using the methodology of 
Blundell et al.
51 
gave a detailed view of its dynamic 3D-structure 
in dilute aqueous solution (Figure 7a).  Overlaying the resulting 
conformers of 1, in which the biaryl axis is free to assume the 
tubulin-binding (aR) configuration, and the bound colchicinoid 
38 in 1SA0 (Figure 7b) indicates that the C(3) methoxy group of 
1 coincides with the carbonyl oxygen of the (distorted) tropolone 
ring. In an alternative comparison (Figure 7c), conformers of 1 
and a model of combretastatin A-4 6 were overlaid with the X- 
ray structure of colchicine 3.
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This provides further support for 
the idea of a distinctive binding motif of 1, in which the C(4) 
xenografts to an extent approaching that displayed by N- 
acetylcolchinol 4, a structurally related allocolchicine derivative 
and recent drug candidate. The phenol 1 has also been shown to 
inhibit the growth of Calu-6 lung tumour xenografts in mice at a 
dose of one-quarter of the nominal MTD. 
On the basis of the tubulin binding model shown in Figure 6, 
the large body of SAR data available for colchicinoids, and the 
characteristics of the compounds that we have prepared to date, 
we propose that the dibenz[c,e]oxepine pharmacophore offers a 
series of colchicinoid analogues with tunable tubulin binding 
characteristics. Exploitation of the IDA strategy (Scheme 2) 
should allow rapid access to new VDAs with design features that 
would prove difficult to achieve by the modification of natural 
colchicinoids. Amides of the form 40 are proposed as a focus for 
further development in this context. 
4. Experimental section 
 
4.1. Chemistry 
 
Melting points were determined using Kofler hot-stage, Buchi 
512 or Stuart Scientific SMP10 equipment and are uncorrected. 
Unless otherwise indicated, IR spectra were recorded for neat 
thin films using Perkin-Elmer 1710FT or Nicolet Nexus 670/870 
spectrometers. NMR spectra were measured using a Bruker 
Avance III 400 spectrometer and are calibrated by reference to 
signals from the solvent (CDCl3  at 77.16 ppm and CD3OD at 
49.00 ppm for 
13
C spectra; residual protium in CDCl3  at 7.26 
ppm, CD3OD at 3.31 ppm and D2O at 4.79 ppm for 
1
H spectra).
53 
Chemical shifts for 
19
F and 
31
P spectra are quoted relative to 
CFCl3 and 85% H3PO4 at 0 ppm respectively. Coupling 
constants (J values) are given in Hz; multiplicities are given as 
singlet (s), doublet (d), triplet (t), quartet (C), quintet (qn) or 
multiplet (m). NMR spectra were assigned with the aid  of 
COSY, HMBC, HMQC and DEPT spectra where appropriate. 
Low-resolution mass spectra were recorded on a Micromass Trio 
2000 instrument using the electrospray ionisation method; data 
for peaks of intensity <20% of that of the base peak are omitted. 
High-resolution (accurate mass) data were recorded using a 
Thermo Finnigan MAT95XP instrument. Elemental analyses 
were carried out by the University of Manchester microanalytical 
service. 
Starting materials and solvents were routinely purified by 
conventional techniques.
54 
Reactions were routinely carried out 
in a nitrogen atmosphere.   Tetrahydrofuran (THF) was dried 
immediately prior to use, by distillation from sodium- 
benzophenone ketyl under nitrogen. Organic  solutions  were 
dried using anhydrous MgSO4 and concentrated by rotary 
evaporation  under  reduced  pressure.     Analytical  thin  layer 
chromatography (TLC) was carried out using Macherey-Nagel 
3.36 (3 H, s, SO2Me), 3.95 (3 H, s, OMe), 7.26 (1 H, dd, J 8.2, 
1.6 Hz, 5-H), 7.38 (1 H, apparent dt, J ca. 8, 0.7 Hz, 4-H), 7.53 
(1 H, dd, J 7.8, 1.6 Hz, 3-H) and 10.33 (1 H, d, J 0.7 Hz, CHO); 
C  (100 MHz, CDCl3) 39.5, 56.6, 118.3, 120.5, 128.2, 131.3, 
140.3, 152.2 and 188.4; Rf  0.35 (EtOAc - hexane, 1:1); Rf  0.57 
(EtOAc - toluene, 1:9, three elutions). 
 
 
4. 1. 1. 2. 3 - Iodo-  2 - formyl-  6 - methoxyphenyl  
methanesu l fona te  ( 23 ) 
To apply the iodination procedure described,
27 
the aldehyde 
22 (2.763 g, 12.0 mol) was dissolved in a warm solvent mixture 
(60 mL; from acetic acid - water - conc. sulfuric acid 100 : 10 : 3 
v/v/v). Iodine (1.28 g, 5.04 mmol) was added, followed by 
periodic acid dihydrate (602 mg, 2.64 mmol). The flask was 
closed with a balloon to retain vapours and the mixture was 
stirred at 60–65 ˚C for 24 h, after which time the dark mixture 
had become a clear red solution. With continued stirring, the 
mixture was diluted with water (50 mL), decolourised by the 
portionwise addition of solid Na2S2O5 (total 500 mg), and poured 
into water (100 mL). The resulting yellow precipitate was 
collected, washed with water and dried at the pump, giving the 
crude title compound 23 (3.71 g, 87%) which was crystallised 
from ethanol (10 mL) and dried in vacuo, giving pale yellow 
prismatic needles (3.19 g, 75%), m.p. 102–104 ˚C (Found: C, 
30.56; H, 2.48; I, 35.81; S, 8.87. C9H9IO5S requires C, 30.35; H, 
2.55; I, 35.63; S, 9.00%); max/cm
–1 3094, 3045, 3020, 3010, 
2941, 2912, 2887, 2841, 1702, 1588, 1563, 1467, 1437, 1390, 
1361, 1325, 1293, 1277, 1218, 1181, 1162, 1120, 1059, 971, 877, 
822, 791, 707; H (400 MHz, CDCl3) 10.05 (1 H, s, CHO), 7.86 
(1 H, d, J 8.8 Hz, 4-H), 6.94 (1 H, d, J 8.8 Hz, 5-H), 3.93 (3 H, s, 
OMe), 3.38 (3 H, s, SMe); C  (100 MHz, CDCl3) 40.0 (CH3), 
56.8 (CH3), 85.3 (C), 118.6 (CH), 130.4 (C), 138.9 (C), 139.7 + + 
Polygram  SIL  G/UV254   plates  and  the  chromatograms  were (CH), 153.4 (C), 192.0 (CH); m/z (ES ) 411 (67%), 379 (MNa , + + 
routinely visualised using UV light (254 nm). Preparative 
column (flash) chromatography was carried out on 60H silica gel 
(Merck  9385)  using  the  flash  technique.
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Compositions  of 
solvent mixtures are quoted as ratios of volume. 'Petroleum' 
refers to a light petroleum fraction, b.p. 60–80 ˚C, unless 
otherwise stated. 'Ether' refers to diethyl ether. Details of the 
preparations of 19 and 20 are provided in Supplementary 
Material. 
 
 
4 .1 .1 .  1. Improved  Ul lmann route to 5 , 7 - 
d ihydro-  3, 9, 10, 11 - te t ramethoxybenz[  c, e 
]oxepin-  4 - ol 1 
 
 
4 .1 .1 .1 .  1. 2 - Formyl-  6 - 
methoxyphenyl  methanesu l fona te  ( 
22 ) 
5 6
 
Methanesulfonyl chloride (17.76 g, 155 mmol, 12.0 mL) was 
added to a solution of o-vanillin (21.60 g, 142 mmol) in 
dichloromethane (200 mL) at 0 °C. The mixture was left to stir 
for 5 min, then triethylamine (17.42 g, 172.2 mmol, 24.0 mL) 
was added dropwise, keeping the internal temperature at 0–5 °C. 
The mixture was stirred for a further 1 h at 0–5 ˚C and then at 
room temperature for a further 0.5 h. The precipitate was 
collected on a Buchner funnel and rinsed with dichloromethane 
(80 mL). The filtrate was washed with water (120 mL), aq. HCl 
(1 M; 2 x 70 mL), saturated sodium hydrogen carbonate (120 
mL) and brine (120 mL). Drying and evaporation under reduced 
pressure gave the crude mesylate 22 (32.0 g, 98%) as a pale 
yellow oil which rapidly solidified.  Crystallisation from ethanol 
(ca. 1 mL/g) gave colourless prisms (two crops, total 26.11 g, 
100), 374 (MH2O , 73), 357 (MH , 18); Rf 0.26 (EtOAc - toluene, 
1:9) [22 has Rf 0.20 under the same conditions]. 
 
 
4. 1. 1. 3. 2 - Iodo-  3, 4 ,5 - t r imethoxybenza ldehyde  ( 24 ) 
To apply the iodination procedure described,
27 
3,4,5- 
trimethoxybenzaldehyde (58.86 g, 0.30 mol) was dissolved by 
warming in a mixture of acetic acid (700 mL) and 2 M sulfuric 
acid (70 mL). Iodine (32.00 g, 126 mmol) was added, followed 
by periodic acid dihydrate (15.04 g, 66 mmol). The flask was 
closed with a septum cap to retain vapours and the mixture was 
stirred for 4 h at 60–65 ˚C, during which the colour changed from 
opaque purple to clear orange-brown. The stirred mixture was 
treated dropwise with a solution made by dissolving Na2S2O5 
(14.5 g, 76 mmol) in water (50 mL) and then poured into water 
(2.0 L). The precipitated solid was collected on  a  Büchner 
funnel, rinsed with water, dried on the filter and then in vacuo, 
giving the aldehyde 24 (76.69 g, 79%) as a cream solid, m.p. 67– 
68 ˚C [lit.
25d 
67 ˚C (cyclohexane)]; H (400 MHz, CDCl3) 10.04 
(1 H, s, CHO), 7.34 (1 H, s, 6-H), 3.96 (3 H, s, OMe), 3.91 (3 H, 
s, OMe), 3.90 (3 H, s, OMe); C (100 MHz, CDCl3) 56.4 (CH3), 
61.2 (CH3), 61.3 (CH3), 91.7 (C), 108.7 (CH), 130.7 (C), 147.9 
(C), 153.1 (C), 154.1 (C), 195.4 (CH); Rf 0.20 (EtOAc - hexane, 
1:4). 
 
 
4. 1. 1. 4. 2, 6'- Di formyl-  4, 2', 3', 4'-  
te t ramethoxyb iphenyl -  3 - yl methanesu l fona te  ( 25 ) 
 
The mesylate 23 (3.56 g, 10.0 mmol) and aldehyde 24 (9.66 g, 
80%), m.p. 78–80 ˚C (lit.
56  
79–80 ˚C);  (400 MHz, CDCl3) 30.0 mmol) were placed in a 100 mL round-bottomed flask and H 
the mixture was melted by gentle heating with a hot-air gun. 
Dendritic copper powder (Aldrich 357456; 20.33 g, 0.32 mol) 
was mixed into the melt using a spatula, and the flask was then 
heated in a Woods metal bath at 185 ˚C for 20 min. The reaction 
mixture was then allowed to cool and extracted with EtOAc (100 
mL). The resulting suspension was filtered through a pad of 
Celite, rinsing  with  EtOAc, and  the filtrate concentrated. 
Chromatography of the residue over silica gel (elution with 
EtOAc  -  hexane,  gradient  1:2  to  1:1)  yielded  4,4',5,5',6,6'- 
hexamethoxy-1,1'-biphenyl-2,2'-dicarboxaldehyde
1  
followed by 
the title compound 25 (2.00 g, 47%), which formed colourless 
prisms, m.p. 132 ˚C (EtOH) [lit.
1 
131–132 ˚C (EtOAc)]; H (400 
MHz, CDCl3) 10.18 (1 H, s, 2-CHO), 9.63 (1 H, s, 6'-CHO), 7.36 
(1 H, s, 5'-H), 7.26 (1 H, d, J 8.5 Hz, 6-H), 7.15 (1 H, d, J 8.5 Hz, 
5-H), 4.03 (3 H, s, OMe), 3.98 (3 H, s, OMe), 3.57 (3 H, s, 
OMe), 3.43 (3 H, s, SMe); C  (100 MHz, CDCl3) 40.0 (CH3), 
56.3 (CH3), 56.6 (CH3), 60.9 (CH3), 61.2 (CH3), 105.9 (CH), 
116.4 (CH), 127.3 (C), 129.7 (C), 130.3 (C), 130.7 (C), 132.1 
(CH), 139.5 (C), 147.3 (C), 150.8 (C), 152.3 (C), 153.8 (C), 
189.0 (CH), 190.2 (CH); Rf  0.20 (EtOAc - hexane, 2:1), 0.30 
(ether). These data are in full accord with those  published 
earlier.
1   
In a small-scale version of this procedure, the mesylate 
A solution of 27 (2.265 g, 5.52 mmol) in THF (35 mL) at 0 ˚C 
under N2 was treated dropwise with 2 M sodium 
hexamethyldisilazide in THF (5.0 mL, 10.0 mmol).
29  
After 5 min 
the solution was cautiously diluted with 2 M aqueous 
hydrochloric acid (12 mL) at 0 ˚C, further diluted with water (20 
mL) and extracted with EtOAc (3 x 30 mL). The combined 
organic extracts were washed with brine (40 mL), dried and 
evaporated. The resulting beige solid was dissolved in 
dichloromethane and the solution filtered through a short column 
of flash silica (h 4 cm, d 3 cm), eluting with dichloromethane. 
The  eluate  gave  the  title  compound  1  (1.37  g,  75%)  as  a 
colourless  solid,  identical  (TLC,  
1
H-NMR,  
13
C-NMR)  to  an 
authentic sample.
1
 
 
 
4 .1 .2 .  2. Int ramolecular  direct  aryla t ion  route  to 1 
 
 
4 .1 .2 .1 .  1. 6 - Bromo- 3 - methoxy-  2 - 
(me thoxy m e tho xy)b en za ld eh yd e ( 29 ) 
 
To a stirred solution of 6-bromo-2-hydroxy-3- 
57 
methoxybenzaldehyde 28 (4.67 g, 20.2 mmol) and 
23 (356 mg, 1.0 mmol) gave the dialdehyde 25 (246 mg, 58%) as 
a colourless solid. 
 
 
4. 1. 1. 5. 2, 6'- Bis(  hydroxymethyl) -  4, 2', 3', 4'-  
te t ramethoxyb iphenyl -  3 - yl methanesu l fona te  ( 26 ) 
 
Sodium   borohydride   (1.25   g,   33.0   mmol)   was   added 
portionwise to a stirred suspension of the dialdehyde 25 (6.37 g, 
15.0 mmol) in MeOH (90 mL) at room temperature. The 
mixture, which became clear and warm, was stirred for a further 
1 h and then diluted with water (120 mL). The bulk of the 
MeOH was removed by rotary evaporation and the residue was 
extracted with EtOAc (3 x 90 mL). The combined extracts were 
washed with brine (90 mL), dried and evaporated. 
Crystallisation of the residue from EtOAc (20 mL) gave a semi- 
solid mass that was broken up using ether (10 mL), collected on a 
filter, rinsed with EtOAc - ether (1:1) and dried in vacuo, giving 
the title compound 26 (4.54 g, 71%) as a white solid, m.p. 124– 
125 ˚C (EtOAc); Rf  (EtOAc - hexane 2:1) 0.18.  Concentration 
diisopropylethylamine (4.90 mL, 3.64 g, 28.1 mmol) in DMF (40 
mL) at 0 ˚C was added dropwise bromomethyl methyl ether (2.00 
mL, 3.062 g, 24.5 mmol). After stirring at 0 ˚C for 10 min and 
then at room temperature for 1 h, the mixture was poured into 
rapidly stirring water (200 mL). The precipitate was collected on 
a filter, washed with water (3 x 40 mL) and dried in vacuo. To 
remove polar impurities, a solution of the crude product (5.28 g) 
in dichloromethane was filtered through a plug of silica gel (3 cm 
diameter, 6 cm depth), eluting with  dichloromethane. 
Evaporation of the eluate provided the title compound 29 (5.10 g, 
92%) as a cream solid, m.p. 69–71 ˚C (EtOH) (Found: C, 43.29; 
H, 3.92; Br, 29.13.  C10H11BrO4  requires C, 43.66; H, 4.03; Br, 
29.05%); max/cm
–1 2944, 2835, 1701, 1573, 1464, 1433, 1301, 
1258, 1157, 1064, 951; H (400 MHz, CDCl3) 10.37 (1 H, d, J 0.5 
Hz, CHO), 7.36 (1 H, dd, J 8.8, 0.5 Hz, 5-H), 6.96 (1 H, d, J 8.8 
Hz, 5-H), 5.17 (2 H, s, OCH2O), 3.87 (3 H, s, ArOMe), 3.55 (3 
H, s, CH2OMe); C (100 MHz, CDCl3) 56.4 (CH3), 58.1 (CH3), 
100.1  (CH2),  113.2  (C),  117.4  (CH),  129.2  (C),  129.8  (CH), 
148.9   (C),   152.5   (C),   190.8   (CH);   m/z   (ES
+
)   340/338 
+ + 
and trituration of the residue with EtOAc - ether (1:3) gave a 
further 0.80 g (12%) of the product, which was identical (
1
H- 
NMR, 
13
C-NMR) to material prepared previously.
1
 
 
 
4. 1. 1. 6. 5, 7 - Dihydro-  3, 9, 10, 11 - 
te t ramethoxybenz[  c,e] oxepin-  4 - yl methanesu l fona te  
( 27 ) 
To a solution of 26 (4.285 g, 10.0 mmol) in acetonitrile (50 
mL) was added 48% aq. hydrobromic acid (2.5 mL, 22 mmol) 
and the solution was stirred at 50–55 ˚C for 1 h. Water (50 mL) 
and dichloromethane (40 mL) were added, the layers were 
separated and the aqueous layer was extracted with 
dichloromethane (40 mL). The extracts were combined, washed 
with brine (40 mL), dried and concentrated, giving the title 
compound 27 (4.035 g, 98%) as a colourless crystalline solid, 
m.p. 158–161 ˚C (MeOH), identical (TLC, 
1
H-NMR, 
13
C-NMR) 
to an authentic sample.
1
 
 
 
4. 1. 1. 7. 5, 7 - Dihydro-  3, 9, 10, 11 - 
te t ramethoxybenz[  c,e] oxepin-  4 - ol ( 1)  
(MNa2H2O ,  100%),  299/297  (MNa ,  80);  Rf   0.27  (EtOAc  - 
hexane, 1:3). 
 
 
4 .1 .2 .2 .  2. (6 - Bromo-  3 - methoxy-  2 - 
(me thoxy m e tho xy)ph en y l )m e thano l (30 ) 
 
A stirred solution of the aldehyde 29 (4.125 g, 15.0 mmol) in 
MeOH (75 mL) at room temperature was treated portionwise 
with sodium borohydride (0.76 g, 20 mmol). The solution was 
stirred for a further 2 h and then poured into water (200 mL). 
The mixture was extracted with dichloromethane (3 x 30 mL) 
and the extract dried and concentrated. Removal of the final 
traces of solvent in vacuo gave the title compound 30 (3.714 g, 
89%) as a colourless oil which slowly solidified. The analytical 
sample had m.p. 60–62 ˚C (EtOAc - hexane, 1:4) (Found: C, 
43.56; H, 4.67; Br, 28.73.   C10H13BrO4  requires C, 43.34; H, 
4.73; Br, 28.83%); max/cm
–1 3457, 2941, 2837, 1576, 1465, 
1437, 1399, 1298, 1269, 1231, 1197, 1159, 1071, 1011, 960, 924, 
799; H (400 MHz, CDCl3) 7.31 (1 H, d, J 8.8 Hz, 4-H), 6.77 (1 
H,  d,  J  8.8  Hz,  5-H),  5.09  (2  H,  s,  OCH2O),  4.81  (2  H,  s, 
ArCH2O), 3.83 (3 H, s, ArOMe), 3.59 (3 H, s, CH2OMe); C (100 
MHz, CDCl3) 56.1 (CH3), 57.8 (CH3), 60.0 (CH2), 99.6 (CH2), 
113.2 (CH), 115.4 (C), 128.8 (CH), 134.9 (C), 146.2 (C), 151.8 
(C); m/z (ES
+
) 301/299 (MNa
+
, 100%); Rf 0.18 (EtOAc - hexane, 
1:2). 
 
 
4 .1 .2 .3 .  3. 5 - Bromomethy l -  1, 2, 3 - 
tr imethoxybenzene  (31 ) 
5 8
 
To a stirred solution of 3,4,5-trimethoxybenzyl alcohol (10.0 
g, 50.5 mmol) in dry dichloromethane (150 mL) under N2 at –5 
˚C was added dropwise a solution of phosphorus tribromide (3.50 
mL, 10.1 g, 37.2 mmol) in dichloromethane (10 mL). After 
stirring at –5 ˚C for 45 min, the mixture was poured on to ice 
(200 g), neutralised with sat. aq. NaHCO3 (120 mL), and the 
organic layer was separated. The aqueous phase was extracted 
with dichloromethane (2 x 20 mL) and the combined organic 
phases were washed with brine (30 mL), dried and concentrated 
to obtain the title compound 31 (13.0 g, 99%) as a colourless 
solid, m.p. 76–78 ˚C (hexane) [lit.
58b 
86–87 ˚C (petroleum)]; H 
(400 MHz, CDCl3) 6.61 (2 H, s, 4-H and 6-H), 4.54 (2 H, s, 
CH2Br), 3.86 (6 H, s, 1-OMe and 3-OMe), 3.84 (3 H, s, 2-OMe) 
(in accord with published data
43
); C  (100 MHz, CDCl3) 34.4, 
56.2, 61.0, 106.2, 133.3, 138.2, 153.4. 
 
 
4 .1 .2 .4 .  4. 1 - Bromo- 4 - methoxy-  3 -
(methoxymethoxy) -  2 - (((3 , 4 , 5 - t r imethoxyphenyl)  
methoxy)  methyl)  benzene (32 ) 
To a stirred suspension of sodium hydride (60% dispersion in 
mineral oil; 750 mg, 18.75 mmol) in THF (45 mL) under N2 at 
room temperature was added dropwise a solution of the alcohol 
30 (2.08 g, 7.5 mmol) in THF (9 mL). After stirring at room 
temperature for 1.5 h, the mixture was treated dropwise with a 
solution of the bromide 31 (2.35 g, 9.0 mmol) in THF (9 mL) and 
the stirred mixture was heated at 45 ˚C for 2.5 h.  It was then 
poured into water (180 mL) and extracted with dichloromethane 
(3 x 60 mL). The combined organic phases were washed with 
water (90 mL) and brine (90 mL), dried and evaporated. 
Chromatography of the residue over silica gel (elution with 
EtOAc - hexane, 1:3) gave the title compound 32 (2.95 g, 86%) 
as   a   colourless   viscous   oil   (Found:   M+Na
+
,   479.0678; 
C20H25BrO7Na  requires  479.0681);  max/cm
–1  2939,  2838, 
1592, 1505, 1463, 1422, 1397, 1355, 1330, 1273, 1234, 1152, 
1128, 1101, 1072, 1008, 957, 829, 805, 780, 691; H (400 MHz, 
h, after which the DMA was evaporated in vacuo. The residue 
was diluted with EtOAc and the solution filtered through a plug 
of silica gel, eluting with more EtOAc. Evaporation of the eluate 
and chromatography of the residue, eluting with acetone - hexane 
(1:4), provided the title compound 34 (127 mg, 56%) as 
colourless crystals, m.p. 112–114 ˚C (MeOH) (Found: C, 64.04; 
H, 6.47.   C20H24O7  requires C, 63.82; H, 6.43%); max/cm
–1
 
2937, 2855, 1599, 1579, 1482, 1462, 1436, 1401, 1370, 1333, 
1304, 1274, 1242, 1225, 1196, 1154, 1116, 1089, 1060, 991, 968, 
798, 734; H  (400 MHz, CDCl3) 7.43 (1 H, d, J 8.6 Hz, 1-H), 
7.00 (1 H, d, J 8.6 Hz, 2-H), 6.75 (1 H, s, 8-H), 5.22 (1 H, br d, J 
5.6 Hz, OCHO), 5.18 (1 H, br d, J 5.6 Hz, OCHO), 5.10 (1 H, d, 
J 11.2 Hz, 5-H), 4.39 (1 H, d, J 11.3 Hz, 7-H), 4.04 (1 H, d, J 
11.2 Hz, 7-H), 3.94 (3 H, s, OMe), 3.92 (3 H, s, OMe), 3.91 (3 H, 
s, OMe), 3.83 (1 H, d, J 11.2 Hz, 5-H), 3.66 (3 H, s, OMe), 3.64 
(3 H, s, OMe); C  (100 MHz, CDCl3) 56.0 (CH3), 56.2 (CH3), 
57.8 (CH3), 60.3 (CH2), 61.0 (CH3), 61.2 (CH3), 67.9 (CH2), 99.6 
(CH2), 108.8 (CH), 111.9 (CH), 125.8 (CH), 126.4 (C), 129.4 
(C), 130.5 (C), 131.1 (C), 142.7 (C), 144.0 (C), 150.7 (C), 151.6 
(C), 152.9 (C); m/z (ES
+
) 399 (MNa
+
, 100); Rf  0.21 (acetone - 
hexane, 1:4) [1 has Rf 0.16 (acetone - hexane, 1:4)]. 
 
 
4. 1. 2. 6. 5, 7 - Dihydro-  3, 9, 10, 11 - 
te t ramethoxybenz[  c,e] oxepin-  4 - ol ( 1)  
 
A solution of 34 (127 mg, 0.34 mmol) in MeOH (3 mL) and 2 
M hydrochloric acid (1 mL, 2 mmol) was heated to 50–55 ˚C for 
1.5 h, after which TLC (acetone - hexane 1:3) indicated that no 
34 remained. The solution was diluted with water (5 mL) and 
extracted with dichloromethane (3 x 5 mL). The combined 
organic extract was washed with brine (10 mL), dried and 
evaporated. Chromatography of the residue, eluting with hexane 
- EtOAc (2:1), gave the title compound 1 (90 mg, 80%), identical 
(TLC, 
1
H NMR) to that obtained from 27 as described above. 
 
 
4. 1. 3. Preparat ive  route  to 15 
 
 
4. 1. 3. 1. 5, 7 - Dihydro-  3, 9, 10, 11 - 
te t ramethoxyd ibenz[  c , e ]oxepin-  4 - yl 
bis(  phenylmethy l)  phosphate  ( 35 ) 
33 
CDCl3) 7.30 (1 H, d, J 8.8 Hz, 5-H), 6.77 (1 H, d, J 8.8 Hz, 6-H), The method of Silverberg et al. was adapted thus:  A three- 
6.65 (2 H, s, 2'-H, 6'-H), 5.10 (2 H, s, OCH2O), 4.72 (2 H, s, 
OCH2), 4.55 (2 H, s, CH2O), 3.86 (6 H, s, ArOMe), 3.822 (3 H, s, 
ArOMe), 3.818 (3 H, s, ArOMe), 3.52 (3 H, s, CH2OMe); C (100 
MHz, CDCl3) 56.0 (CH3), 56.1 (2 x CH3), 57.7 (CH3), 60.8 
(CH3), 66.7 (CH2), 72.9 (CH2), 99.6 (CH2), 104.8 (2 x CH), 113.5 
(CH), 116.7 (CBr), 128.4 (CH), 131.6 (C), 134.2 (C), 137.3 (C), 
146.3 (C), 151.9 (C), 153.2 (2 x C); m/z (ES
+
) 481/479 (MNa
+
, 
100%); Rf 0.18 (EtOAc - hexane, 1:2). 
 
 
4. 1. 2. 5. 5, 7 - Dihydro-  1, 2, 3, 9 - te t ramethoxy-  8 - 
(methoxymethoxy)d ibenz[  c , e] oxepine (34 ) 
In an adaptation of the procedure described by Fagnou et al.,
30
 
the  ether  32  (276.2  mg,  0.604  mmol),  anhydrous  potassium 
carbonate (powdered, 167 mg, 1.21 mmol), DavePhos 33 (23.6 
mg, 0.06 mmol) and palladium acetate (13.5 mg, 0.06 mmol) 
were placed in a round-bottomed flask. The flask was purged 
with nitrogen for 10 min and DMA (12 mL) was added. The 
solution was then heated, darkening above 130 ˚C to black at 145 
˚C. TLC (EtOAc - hexane, 1:2) after 21 h at 145 ˚C suggested 
that the reaction was incomplete.  Heating was continued for 67 
necked  flask  fitted  with  a  thermometer,  nitrogen  inlet  and 
magnetic stirrer was charged with 1 (1.460 g, 4.39 mmol, 1.0 
eq.), N,N-dimethylaminopyridine (60 mg, 0.49 mmol, 0.11 eq.) 
and anhydrous acetonitrile (25 mL). The resulting solution was 
cooled to an internal temperature of –10 ˚C (cooling bath of 
acetone, water and solid CO2 pellets) and treated with anhydrous 
tetrachloromethane (2.1 mL, 3.35 g, 22 mmol, 5 eq.) followed by 
diisopropylethylamine (1.6 mL, 1.19 g, 9.2 mmol, 2.1 eq.). The 
mixture was stirred for 1 min and then treated dropwise with 
dibenzyl phosphite (1.4 mL, 1.66 g, 6.3 mmol, 1.44 eq.), keeping 
the mixture at or below –10 ˚C. The mixture was then stirred at – 
10 ˚C for a further 40 min, at which point TLC indicated the 
consumption of the organic starting materials. The mixture was 
quenched at –10 ˚C by the dropwise addition of a solution of 
potassium dihydrogen phosphate (0.68 g) in water (10 mL), 
allowed to warm to room temperature, and then extracted with 
EtOAc (3 x 30 mL). The combined organic phase was washed 
with water (40 mL) and brine (40 mL), dried and concentrated. 
The residue was purified by chromatography (silica gel 
preconditioned with EtOAc - hexane - Et3N 50:50:1), eluting 
with EtOAc - hexane (1:1 to 3:2), which gave the title compound 
35 (2.06 g, 79%) as a white crystalline solid, m.p. 132–133 ˚C 
(EtOH) (Found: C, 64.88; H, 5.38; P, 5.18. C32H33O9P requires C, 
64.86; H, 5.61; P, 5.23%) (M+H
+
, 593.1943. C32H34O9P requires 
593.1940); max/cm
–1  
2943, 2858, 1482, 1461, 1278; H  (400 
MHz, CDCl3) 7.52 (1 H, dd, J 8.6, 1.2 Hz, 1-H), 7.40–7.29 (10 
H, m, ArH), 7.04 (1 H, d, J 8.6 Hz, 2-H), 6.75 (1 H, s, 8-H), 
5.28–5.20 (4 H, m, OCH2Ph), 5.12 (1 H, d, J 11.4 Hz, 5-H), 4.39 
(1 H, d, J 11.3 Hz, 7-H), 4.04 (1 H, d, J 11.3 Hz, 7-H), 3.95 (3 H, 
s, OMe), 3.92 (3 H, s, OMe), 3.86 (3 H, s, OMe), 3.84 (1 H, d, J 
11.4 Hz, 5-H), 3.66 (3 H, s, OMe); C  (100 MHz, CDCl3) 56.1 
(CH3), 56.2 (CH3), 60.1 (5-CH2), 61.0 (CH3), 61.2 (CH3), 67.9 
(7-CH2), 69.80 (PhCH2), 69.86 (PhCH2), 108.8 (8-CH), 112.2 (2- 
CH), 125.9 (C), 127.1 (two peaks, 1-CH), 127.9 (Ph 2,6- or 3,5- 
CH), 128.2 (C), 128.2 (C), 128.5 (Ph 4-H), 128.6 (Ph 2,6- or 3,5- 
CH), 130.5 (C), 131.1 (C), 138.3 (C), 138.4 (C), 142.7 (C), 150.3 
(C), 150.3 (C), 150.7 (C), 153.1 (C); P (162 MHz, CDCl3) –5.77 
(quin, J 7.5 Hz); m/z (CI, NH3) 593 (MH
+
, 10%); Rf 0.22 (EtOAc 
- petroleum ether 60–80˚ 1:1). 
 
 
4. 1. 3. 2. 5, 7 - Dihydro-  3, 9, 10, 11 - 
te t ramethoxyd ibenz[  c,e] oxepin-  4 - ol 4 - (d ihydrogen  
phosphate)  ( 36 ) 
A solution of 35 (1.481 g, 2.5 mmol) in MeOH (65 mL) and 
EtOAc (10 mL) containing palladium on charcoal (10% w/w; 70 
mg) at room temperature was stirred under an atmosphere of 
hydrogen for 1 h, at which point TLC (EtOAc) indicated that the 
starting material had been consumed. The solution was filtered 
through a pad of Celite (depth 8 mm), rinsing with MeOH, and 
evaporated. The residue was triturated with EtOAc and the solid 
collected on filter, washed with EtOAc and dried in vacuo, giving 
the title compound 36 (984 mg, 95%) which crystallised from 
EtOH as colourless rosettes, m.p. >200 ˚C (dec.) (Found: C, 
52.36; H, 5.20; P, 7.52. C18H21O9P requires C, 52.43; H, 5.13; P, 
7.51%) (M+Na
+
, 435.0826.   C18H21O9PNa requires 435.0821); 
max/cm
–1 
2930, 2858, 1590, 1107; H (400 MHz, CD3OD) 7.46 
(1 H, dd, J 8.6, 1.2 Hz, 1-H), 7.16 (1 H, d, J 8.6 Hz, 2-H), 6.89 (1 
H, s, 8-H), 5.15 (1 H, d, J 11.1 Hz, 5-H), 4.41 (1 H, d, J 11.1 Hz, 
7-H), 3.96 (1 H, d, J 11.1 Hz, 7-H), 3.93 (3 H, s, OMe), 3.91 (3 
H, s, OMe), 3.89 (3 H, s, OMe), 3.81 (1 H, d, J 11.1 Hz, 5-H), 
3.61 (3 H, s, OMe); C  (100 MHz, CD3OD) 56.5 (CH3), 56.6 
(CH3), 61.0 (5-CH2), 61.3 (CH3), 61.5 (CH3), 68.4 (7-CH2), 110.1 
(CH), 113.3 (CH), 127.3 (C), 127.8 (CH), 129.2 (C), 131.4 (C), 
132.2 (C), 140.0 (C), 140.1 (C), 144.1 (C), 151.8 (C), 152.3 (C), 
154.5  (C);  P   (162  MHz,  CD3OD)  –4.81  (s);  m/z  (ES)  435 
(MNa
+
, 80%). 
 
 
4. 1. 3. 3. 5, 7 - Dihydro-  3, 9, 10, 11 - 
te t ramethoxyd ibenz[  c,e] oxepin-  4 - ol 4 - (d isodium 
phosphate)  ( 15)  
A stirred solution of the dihydrogen phosphate 36 (731 mg, 
1.773 mmol) in MeOH (12 mL) was treated with methanolic 
sodium methoxide (0.3984 M, 8.90 mL, 3.546 mmol) [prepared 
by dissolving freshly cut sodium (2.29 g, 99.6 mmol) in 
anhydrous MeOH (250 mL)]. The mixture was stirred for 2 min, 
then concentrated by rotary evaporation. The residue was 
triturated with ethanol - hexane (1:1) and dried in vacuo, giving 
the title compound 15 (802 mg, 99%) as a white powder, m.p. 
208–215 ˚C (darkens above 180 ˚C) (Found: C, 45.50; H, 4.81; 
Na, 8.35; P, 6.39. C18H19Na2O9P requires C, 47.38; H, 4.20; Na, 
10.08; P, 6.79%);* (400 MHz, D2O) 7.13 (1 H, dd, J 8.6, 1.0 Hz, 
1-H), 7.05 (1 H, d, J 8.6 Hz, 2-H), 6.87 (1 H, s, 8-H), 5.29 (1 H, 
d, J 11.1 Hz, 5-H), 4.31 (1 H, d, J 11.1 Hz, 7-H), 3.84 (3 H, s, 
OMe), 3.83 (3 H, s, OMe), 3.81 (3 H, s, OMe), 3.76–3.69 (2 H, 
m, 5-H and 7-H), 3.58 (3 H, s, OMe); C (100 MHz, D2O) 55.7 
(CH3), 56.0 (CH3), 59.9 (5-CH2), 61.1 (CH3), 61.2 (CH3), 66.5 
(7-CH2), 109.3 (CH), 112.4 (CH), 124.5 (CH), 126.3 (C), 127.8 
(C), 129.1 (C), 130.6 (C), 135.9 (C), 140.9 (C), 141.6 (C), 149.3 
(C), 151.5 (C), 152.1 (C); P (162 MHz, D2O) –0.45 (s). 
* The elemental analysis result corresponds to a solvate with a 
w/w distribution of 15 (93.0%), water (3.7%), methanol (3.3%); 
compound 15 is hygroscopic. 
 
 
4. 1. 4. Preparat ive  route  to 18 
 
 
4. 1. 4. 1. 5, 7 - Dihydro-  3, 9, 10, 11 - 
te t ramethoxyd ibenz[  c,e] oxepin-  4 - yl 
tr i f luoromethanesu l fonate  ( 18 ) 
To a 5 mL flask containing the dibenzoxepinol 1 (83.2 mg, 
0.25 mmol, 1.0 eq.) and anhydrous pyridine (0.28 mL, 274 mg, 
3.46 mmol, 13.8 eq.) in dry dichloromethane (0.3 mL) under 
argon was added triflic anhydride (0.053 mL, 89 mg, 0.315 
mmol, 1.26 eq.) dropwise at 0 ˚C over a period of 2–3 min. After 
stirring the mixture at this temperature for 30 min, TLC indicated 
the consumption of starting material. The  mixture  was 
transferred to a separating funnel containing dichloromethane (2 
mL) and 1 M hydrochloric acid (2 mL). The organic layer was 
collected and washed with more 1 M hydrochloric acid (2 x 1 
mL), saturated aqueous sodium hydrogen carbonate (1 mL) and 
brine (0.5 mL), dried and concentrated in vacuo to afford a dark 
yellow oil. Chromatography (EtOAc - petroleum, 1:2) afforded 
the title compound 18 (90.6 mg, 78%) as a white solid, m.p. 164 
˚C (M, 464.0748.   C19H19F3O8S requires 464.0753); max/cm
–1
 
2943, 2866, 1596, 1486, 1412, 1329; H (400 MHz, CDCl3) 3.69 
(3 H, s, OMe), 3.92 (1 H, d, J 11.5 Hz, 5-H), 3.93 (3 H, s, OMe), 
3.95 (3 H, s, OMe), 3.98 (3 H, s, OMe), 4.00 (1 H, d, J 11.5 Hz, 
7-H), 4.43 (1 H, d, J 11.5 Hz, 7-H), 4.90 (1 H, d, J 11.5 Hz, 5-H), 
6.76 (1 H, s, 8-H), 7.12 (1 H, d, J 8.7 Hz, 2-H), 7.67 (1 H, d, J 
8.7 Hz, 1-H); C (100 MHz, CDCl3) 56.2 (CH3), 56.4 (CH3), 59.9 
(CH2), 61.1 (CH3), 61.3 (CH3), 68.0 (CH2), 98.5 (C), 99.7 (C), 
109.0 (CH), 112.5 (CH), 125.0 (C), 129.1 (C), 130.1 (CH), 131.0 
(C), 136.9 (C), 142.9 (C), 150.4 (C), 150.7 (C), 153.6 (C); F 
(375  MHz,  CDCl3)  –77.98;  m/z  (EI)  464  (M,  10%);  Rf  0.35 
(EtOAc - petroleum, 1:2). 
 
 
4.2. Biological Evaluation 
 
 
4 .2 .1 .  1. Inhibi t ion  of tubulin assembly  and K 
526 growth inhibi t ion  assays  
Details of the procedures are described in detail elsewhere.
1
 
 
 
4 .2 .2 .  2. In v itro  screening  against  NCI cell  l ines  
Compounds 1 and 15–17 were submitted to the US National 
Cancer Institute (NIH, Bethesda, Maryland) for screening against 
the NCI-60 panel of human cancer cell lines, a service offered 
through the Developmental Therapeutics Program (DTP). Full 
details of the methodology for compound testing, data analysis 
and use of the COMPARE algorithm are available on the NCI 
website.
45   
Compounds 1 and 15–17 were tested more than once 
in NCI-60 5-dose assays, and the average data were used in 
COMPARE analyses. All of these were run with the GI50 values 
as the target-set endpoints and the default settings: Minimum 
correlation 0.2; count results to return 50; minimum count 
common cell lines, 40; minimum standard deviation, 0.05. 
The test results for 1 and 15–17 were subjected to a matrix 
COMPARE analysis
42 
together with the colchicinoids 2–4 and 
the combretastatins 6 and 7.  In this type of analysis, the profile 
of antiproliferative activity of the 'seed' compound against the 
panel of cancer cell lines in the NCI-60 in vitro assays is 
compared with that of the 'target' compound in the same assays. 
The NSC numbers used to retrieve the data for this analysis were: 
1, NSC 756015; 15, NSC 756016; 16, NSC 756013; 17, NSC 
756014. Data for 2–4, 6 and 7 are available in the NCI 
collection. The results provided the source data for Tables 3a 
and 3b. 
other tumour was immersion fixed in 10% neutral buffered 
formalin for 24 h and processed for paraffin embedding. The 
control group were processed at the same time as the 24 h time- 
point. Frozen sections of 10 m thickness were taken at 
approximately 100 m intervals through the tumour, with each 
tumour being attributed a random number so that examination 
was done blind. Up to five fields from  each of 10 random 
sections were examined for each tumour under UV illumination 
using a Leica DMRB microscope, with images captured digitally 
through a JVC 3-CCD camera and processed using AcQuis 
(Synoptics, Cambridge, UK) software.   Functional vasculature 
2 
Using the standard COMPARE protocol, the antiproliferative was assessed by placing a cm grid over the captured digital 
activity profiles of the 1 and 15–17 were compared with those of 
the NCI standard agents collection of anticancer agents. For 
perspective, the analysis was also carried out with 2–4, 6 and 7 as 
the seeds. The results provided the source data for Table 3c. 
All of the relevant data, including the complete Table 2, are 
provided in the Supplementary Material. 
 
 
4 .2 .3 .  3. In v ivo ant i vascular  ef fects  of 15 
Female Balb/C immunodeficient nude mice (Harlan UK Ltd., 
Blackthorn, UK) aged 6-12 weeks were kept in cages housed in 
isolation cabinets in an air-conditioned room with regular 
alternating cycles of light and darkness. They received Teklad 
2018 diet (Harlan) and water ad libitum. Accurately weighed 
amounts of 15 or 21 were dissolved in sterile water and 
administered  within  15  minutes  of  addition  of  solvent.    To 
determine the MTD, 15 was administered intravenously on days 
0, 2 and 4 at 200 or 400 mg kg
–1 
to groups of 2 mice, with a 
control  group  remaining  untreated.     Mice  were  frequently 
weighed and monitored for any visible deleterious effects for 14 
d following administration. Percentage bodyweight compared to 
bodyweight on day 0 was determined. No major loss in 
bodyweight or other deleterious effects were observed at either of 
the concentrations of 15 administered. A persistent reduction in 
percentage bodyweight to 85% of starting weight would be 
considered toxic. Tumours were excised from a donor animal, 
placed in sterile physiological saline containing penicillin and 
streptomycin  and  cut  into  small  fragments  of  approximately 
2 mm
3
.   Under brief general isoflurane inhalation anaesthesia, 
DLD-1 fragments were implanted in both the left and right flanks 
of each mouse using a trocar. Once tumours had reached a 
volume of approximately 150 mm
3 
(as measured by callipers), to 
ensure that an established tumour vascular network was in place, 
the  mice  were  allocated  into  groups  of  three  by  restricted 
randomisation to keep group mean tumour size variation to a 
minimum. 
Vascular shutdown: Seven groups of tumour-bearing mice 
(n=3 per group) were used to assess the effects of treatment with 
the compounds on the functional vasculature in DLD-1 tumours. 
Once tumours had reached a volume of approximately 150 mm
3
, 
to ensure that an established tumour vascular network was in 
place, mice were treated with a single 400 mg kg
–1 
intravenous 
dose of 15 or 21 (three groups per compound).   An untreated 
group was maintained as a control (one group). At 1, 4 or 24 h 
following treatment (n=3 per group), vascular shutdown was 
assessed as follows: Hoechst 33342 dye was dissolved in sterile 
saline and injected intravenously by the tail vein at 40 mg kg
–1
. 
One minute after injection the mice in the relevant treatment 
group were sacrificed by cervical dislocation and the tumours 
carefully and rapidly excised. One tumour from each mouse was 
then wrapped in aluminium foil, immediately immersed in liquid 
nitrogen and stored at 80 ˚C until ready for ultracryotomy.  The 
image and counting the number of points on the grid which 
overlay fluorescently stained cells. The percentage functional 
vasculature was then calculated by taking the total number of 
fluorescence-positive points for each field and dividing by the 
total number of points. An average percentage for each animal 
was calculated. Comparisons were made between percentage 
vasculature in control and treated tumours. Statistical analysis of 
shutdown was carried out using a two-tailed Student’s t-Test. 
The results are shown in Figure 1. 
Tumour necrosis: For each animal, 5 m thick paraffin 
sections were taken and stained with haematoxylin and eosin to 
assess for necrosis. Each tumour was attributed a random 
number so that examination was done blind. Digital images were 
captured using the same system as above but with bright-field 
illumination. Percentage necrosis was assessed by placing a cm
2 
grid over the captured digital image and counting the number of 
points on the grid which overlay necrotic cells. The percentage 
necrosis was calculated by taking the total number of necrosis- 
positive points for each field and dividing by the total number of 
points. An average percentage for each animal was then 
calculated. Statistical analysis of shutdown was carried out using 
a two-tailed Student’s t-Test. The results are shown in Figure 2. 
See Figures 3 and 4 for sample images and Supplementary 
Material for further data. 
 
 
4 .2 .4 .  4. In v ivo ant i tumour  effects  of 1 
Calu-6 human lung carcinoma cells (American Type Culture 
Collection, Manassas, VA, USA) were cultured in RPMI 
supplemented with 10% FCS and 2 mmol/L glutamine. Cells 
were harvested in exponential phase growth and prepared at a 
concentration of 2 × 107 cells/mL in a 1:1 mix of serum-free 
RPMI and Matrigel (phenol red-free; BD Biosciences, 
Erembodegem,  Belgium). 
To initiate tumour xenografts, 0.1 mL of cell suspension was 
implanted at an approximate depth of 1 mm under the skin 1 cm 
from the tail base of female nu/nu CBA mice aged 10 to 12 wk. 
Palpable tumours were evident 5–7 days after cell implantation. 
Tumour volume was measured daily using calipers. Once a 
tumour volume of approximately 250 mm3 was attained, tumours 
were randomised into 3 treatment groups (n=6/group): vehicle 
(5% DMSO in peanut oil), compound  1 at 0.5 MTD in 5% 
DMSO/peanut oil and compound 1 at 0.25 MTD in 5% 
DMSO/peanut oil. Compound/vehicle was administered IP at 0.1 
mL per 10 g body weight on days 1 and 5. Mouse condition and 
body weight were monitored daily and the animals maintained 
throughout using the highest welfare standards. 
All procedures had local ethics and Home Office approval and 
were conducted under PPL 40/2328. 
4 .2 .5 .  5. Dynamic  3D- solut ion  s t ructure  of 1 
Details of this analysis, which utilised the methodology of 
Blundell et al.,
51 
are provided in the Supplementary Material. 
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 3 
General Experimental Information 
Melting points were determined using Buchi 512 or Stuart Scientific SMP10 
equipment and are uncorrected.  Unless otherwise indicated, IR spectra were recorded 
for neat thin films on NaCl plates, using Perkin-Elmer FT-IR Spectrum RX1 or BX 
spectrometers.  NMR spectra were measured using a Bruker Avance III 400 
spectrometer and are calibrated by reference to signals from the solvent (CDCl3 at 
77.16 ppm and CD3OD at 49.00 ppm for 13C spectra; residual protium in CDCl3 at 
7.26 ppm, CD3OD at 3.31 ppm and D2O at 4.79 ppm for 1H spectra).53  Chemical 
shifts for 19F and 31P spectra are quoted relative to CFCl3 and 85% H3PO4 at 0 ppm 
respectively.  Coupling constants (J values) are given in Hz; multiplicities are given 
as singlet (s), doublet (d), triplet (t), quartet (C), quintet (qn) or multiplet (m).  NMR 
spectra were assigned with the aid of COSY, HMBC, HMQC and DEPT spectra 
where appropriate.  Low-resolution mass spectra were recorded on a Micromass Trio 
2000 instrument using the electrospray ionisation method; data for peaks of intensity 
<20% of that of the base peak are omitted.  High-resolution (accurate mass) data were 
recorded using a Thermo Finnigan MAT95XP instrument.  Elemental analyses were 
carried out by the University of Manchester microanalytical service.   
 
Reactions were routinely carried out under nitrogen.  Most reagents and solvents were 
used as supplied commercially.  Anhydrous THF was distilled from sodium - 
benzophenone ketyl immediately before use.54  Organic solutions were dried using 
anhydrous magnesium sulfate and concentrated by rotary evaporation.  Analytical thin 
layer chromatography (TLC) was carried out using Macherey-Nagel Polygram SIL 
G/UV254 plates and the chromatograms were routinely visualised using UV light (254 
nm) and alkaline aq. KMnO4.  Preparative column (flash) chromatography was 
carried out on 60H silica gel (Merck 9385) using the flash technique.55  Compositions 
of solvent mixtures are quoted as ratios of volume.  'Ether' refers to diethyl ether.  
'Petroleum' refers to a fraction of light petroleum, b.p. 60–80 ˚C, unless indicated 
otherwise.  
 
 
 4 
Section 4.1.5.  Preparation of 19 and 20 
 
 
 
4,5,6-Trimethoxy-4'-nitro-1,1'-biphenyl-2,2'-dimethanol 43 
A mixture of 2-chloro-5-nitrobenzaldehyde 41 (Aldrich; 241.9 mg, 1.30 mmol) and 2-
bromo-3,4,5-trimethoxybenzaldehyde 4228 (1.00 g, 3.64 mmol) in dry DMF (2 mL) 
was added to a stirred, boiling suspension of copper bronze (0.91 g, 14.3 mmol) in dry 
DMF (5 mL) over a period of 30 min.  After 8 h TLC (EtOAc - petroleum, 1:4) 
indicated the consumption of the starting materials.  The mixture was cooled, passed 
through a Celite plug and diluted with toluene, which was distilled off to afford a dark 
oil.  Chromatography (EtOAc - petroleum, 1:2) afforded a sample of 4,5,6-
trimethoxy-4'-nitrobiphenyl-2,2'-dicarbaldehyde 37 (259 mg, 57%) containing traces 
of an unidentified second compound.  This sample of 37 (≤0.75 mmol) was dissolved 
in ethanol (5 mL) and treated with a solution of sodium borohydride (0.2 g, 5.3 mmol) 
in water (1.5 mL).  After stirring for 40 min the mixture was added to 1 M aqueous 
HCl (20 mL).  The precipitated product was collected on a filter, washed with water 
and recrystallised from ethanol, which gave the title compound 43 (113 mg, 25% over 
two steps) as a white powder which was used directly in the next step. 
 
5,7-Dihydro-1,2,3-trimethoxy-9-nitrodibenz[c,e]oxepine 19 
4,5,6-Trimethoxy-4'-nitro-1,1'-biphenyl-2,2'-dimethanol 43 (43.7 mg, 0.125 mmol) in 
50% v/v aqueous H2SO4 (1 mL) was heated in an oil bath of temperature 85 ˚C for 20 
min.  The mixture was cooled, quenched with ice (6 g) and extracted into chloroform 
(4 x 2 mL).  The extract was dried and concentrated in vacuo, giving a dark tan solid.  
Chromatography (EtOAc - petroleum, 1:2) afforded the title compound 19 (39.6 mg, 
37
MeO
MeO
OMe
NO2
CHO
CHO
Cu
DMF
41
Cl
NO2
CHO
42
MeO
OMe
MeO CHO
Br
19  X = NO2
20 X = NH2
H2, Pd-C (90%)
43
MeO
MeO
OMe
NO2
OH
OH H2SO4, H2O85 ˚C, 0.3 h
96%
O
MeO
MeO
OMe
X
NaBH4
EtOH, H2O
25% over
two steps
+
reflux
8 h
 5 
96%) as a tan solid, m.p. 161 ˚C (MH+, 332.1122.  C17H18NO6 requires 332.1129); 
νmax/cm–1 2935, 2856, 1597, 1518; δH (400 MHz, CDCl3) 3.71 (3 H, s, OMe), 3.95 (3 
H, s, OMe), 3.96 (3 H, s, OMe), 3.97–4.03 (1 H, br s, 5-H or 7-H), 4.14–4.23 (1 H, br 
s, 7-H or 5-H), 4.39–4.48 (1 H, br s, 5-H or 7-H), 4.55–4.64 (1 H, br s, 7-H or 5-H), 
6.80 (1 H, s, 4-H), 7.89 (1 H, d, J 8.2 Hz, 11-H), 8.28–8.32 (2 H, m, 8-H and 10-H); 
δC (100 MHz, CDCl3) 56.3 (CH3), 61.28 (CH3), 61.31 (CH3), 67.1 (CH2), 67.7 (CH2), 
109.1 (CH), 123.1 (CH), 124.4 (C), 124.8 (CH), 131.0 (CH), 131.7 (C), 136.4 (C), 
142.9 (C), 144.3 (C), 146.9 (C), 151.0 (C), 154.6 (C); m/z (CI) 349 (M+18, 100%), 
332 (M+H, 17), 319 (20), 302 (41), 272 (44); Rf 0.54 (EtOAc - petroleum, 1:2). 
 
5,7-Dihydro-9,10,11-trimethoxydibenz[c,e]oxepin-3-amine 20 
5,7-Dihydro-1,2,3-trimethoxy-9-nitrodibenz[c,e]oxepine 19 (85.4 mg, 0.258 mmol, 
1.0 eq.) in EtOAc (4 mL) containing palladium on charcoal (10% w/w; 7 mg) was 
stirred under a hydrogen balloon for 24 h until TLC indicated the consumption of 
starting material.  The mixture was passed through a plug of neutral alumina (0.5 cm 
depth in a Pasteur pipette) and concentrated in vacuo to afford the title compound 20 
(70 mg, 90%) as a yellow crystalline solid, m.p. 145 ˚C (M, 301.1305.  C17H19NO4 
requires 301.1314); νmax/cm–1 3461, 3361, 2938, 2852, 1607, 1482; δH (400 MHz, 
CDCl3) 3.66 (3 H, s, OMe), 3.78 (2 H, br s, NH2), 3.91 (3 H, s, OMe), 3.94 (3 H, s, 
OMe), 4.03–4.18 (2 H, br s, 5-H or 7-H), 4.30–4.44 (2 H, br s, 5-H or 7-H), 6.74 (1 H, 
s, 8-H), 6.745 (1 H, d, J 2.5 Hz, 4-H), 6.78 (1 H, dd, J 8.2, 2.5 Hz, 2-H), 7.51 (1 H, d, 
J 8.2 Hz, 1-H); δC (100 MHz, CDCl3) 56.2 (CH3), 60.9 (CH3), 61.2 (CH3), 67.8 
(CH2), 67.9 (CH2), 108.8 (CH), 115.0 (CH), 115.9 (CH), 126.9 (C), 127.2 (C), 130.7 
(CH), 131.1 (C), 136.3 (C), 142.8 (C), 150.7 (C), 152.5 (C) (1 C unresolved); m/z 
(ES) 301 (M, 20%); Rf  0.32 (EtOAc - petroleum, 3:2). 
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Section 4.2.2.  In vitro screening against NCI cell lines 
 
 
 
Compounds 1 and 15–17 were submitted to the US National Cancer Institute (NIH, 
Bethesda, Maryland) for screening against the NCI-60 panel of human cancer cell 
lines, a component of the Developmental Therapeutics Program (DTP).  Full details 
of the methodology for compound testing, data analysis and use of the COMPARE 
algorithm are available in print38 and on the NCI website.45 
 
Testing: Three dose response parameters are calculated for each compound under test: 
(i) Growth inhibition of 50% (GI50) is the drug concentration resulting in a 50% 
reduction in the net protein increase (as measured by sulforhodamine B staining) in 
control cells during the drug incubation.  (ii) The TGI is the drug concentration 
resulting in total growth inhibition.  (iii) The LC50 is the concentration of drug 
resulting in a 50% reduction in the measured protein at the end of the drug treatment, 
as compared to that at the beginning, indicating a net loss of cells following treatment.  
Values are calculated for each of these three parameters if the designated level of 
activity is reached.  If the effect is not reached or is exceeded, the value for that 
parameter is expressed as greater or less than the maximum or minimum 
concentration tested.   
 
Compounds 1 and 15–17 were tested more than once in NCI-60 5-dose assays, and 
the average data were used in COMPARE analyses.  All of these were run with the 
GI50 values as the target-set endpoints and the default settings:  Minimum correlation 
0.2; count results to return 50; minimum count common cell lines, 40; minimum 
standard deviation, 0.05.  The test results are provided in the complete version of 
Table 2 which follows. 
 
  
15
O
MeO
MeO
OMe
OMe
OPO3Na2
16
O
MeO
MeO
OMe
OMe
17
O
MeO
MeO
OMe
O
O
1
O
MeO
MeO
OMe
OMe
OH
A
C
B
5
7
1
 7 
Table 2.  In vitro cell growth inhibition data for dibenzoxepines against the NCI-60 
panel of human cancer cell lines. 
 
  Cell growth inhibition (GI50, µM)a 
Panel Cell line 1 15 16 17 
Leukaemia CCRF-CEM 0.04 0.29 0.08 0.35 
 HL-60(TB) 0.03 0.32 0.04 0.39 
 K-562 0.04 0.28 0.04 0.21 
 MOLT-4 0.06 0.40 0.09 0.47 
 RPMI-8226 0.32 0.46 0.33 0.50 
 SR 0.04 0.19 0.04 0.17 
Non-small cell lung A549/ATCC 0.35 0.42 0.13 0.44 
 EKVX ND 0.68 0.60 0.78 
 HOP-62 0.63 0.79 1.12 0.69 
 HOP-92 0.59 ND >100 7.08 
 NCI-H226 3.47 2.82 1.58 2.75 
 NCI-H23 0.76 0.71 0.44 0.79 
 NCI-H322M 0.52 1.32 2.04 2.00 
 NCI-H460 0.31 0.36 0.17 0.38 
 NCI-H522 0.04 0.30 0.28 0.39 
Colon COLO205 0.50 0.62 0.11 0.34 
 HCC-2998 0.32 0.42 0.22 0.49 
 HCT-116 0.32 0.43 0.05 0.37 
 HCT-15 0.08 0.44 0.08 0.48 
 HT29 ND ND ND ND 
 KM12 0.05 0.30 0.05 0.36 
 SW-620 0.05 0.40 0.05 0.40 
CNS SF-268 0.09 0.79 0.46 1.32 
 SF-295 0.27 0.32 0.06 0.33 
 SF-539 0.05 0.33 0.16 0.35 
 SNB-19 0.14 0.51 0.98 0.68 
 SNB-75 0.07 0.54 0.09 0.46 
 U251 0.30 0.48 0.10 0.48 
Melanoma LOXIMVI 0.08 0.66 0.21 0.87 
 M14 0.05 0.27 0.05 0.23 
 MALME-3M ND 2.51 >100 >100 
 MDA-MB-435 0.03 0.04 0.03 0.05 
 SK-MEL-2 0.26 5.37 0.10 0.56 
 SK-MEL-28 1.58 0.89 0.08 ND 
 SK-MEL-5 0.04 0.26 0.03 0.21 
 UACC-257 >100 4.68 >100 3.39 
 UACC-62 1.00 5.50 0.08 0.79 
Ovarian IGROV1 0.63 4.07 0.85 0.95 
 NCI/ADR-RES 0.05 0.28 0.07 0.36 
 OVCAR-3 0.21 0.28 0.05 0.25 
 OVCAR-4 0.71 1.29 0.74 2.19 
 OVCAR-5 ND ND ND ND 
 OVCAR-8 0.20 0.42 0.31 0.52 
 SK-OV-3 0.07 0.40 0.13 0.47 
Renal 786-0 0.43 0.72 0.34 0.50 
 A498 3.02 18.6 0.17 0.45 
 ACHN ND ND ND ND 
 CAKI-1 0.83 0.79 30.2 56.2 
 RXF393 0.04 0.21 0.08 0.20 
 SN12C 0.21 0.72 0.83 1.05 
 TK-10 >100 ND >100 5.13 
 UO-31 14.5 19.5 15.1 3.98 
Prostate DU-145 0.06 0.39 0.18 0.37 
 PC-3 0.28 0.56 0.48 0.54 
Breast BT-549 0.26 2.24 0.20 0.54 
 HS578T 0.04 0.24 0.24 0.43 
 MCF7 0.07 0.40 0.04 0.40 
 MDA-MB-231/ATCC 0.27 0.71 0.59 1.20 
 MDA-MB-468 0.22 1.15 0.03 0.17 
 T-47D 33.9 8.51 >100 25.7 
a GI50: concentration required for 50% cell growth inhibition; ND = not determined. 
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Section 4.2.2.  Matrix COMPARE analysis  
(i) The dibenzoxepines 1 and 15–17 were subjected to a matrix COMPARE analysis42 
together with the colchicinoids 2–4 and the combretastatins 6 and 7.  Data for 2–4, 6 
and 7 are available in the NCI collection.  The results, shown below, provided the 
source data for Tables 3a and 3b.  
 
    Target vector identity 
    
22
03
39
 
18
60
52
 
16
85
 
36
72
92
 
32
34
13
 
90
73
1 
32
34
81
 
14
88
99
 
98
12
1 
Seed vector identity 1 15 16 17 2 3 4 6 7 
220339 
NSC:S756015 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
1 1.00 0.81 0.84 0.79 0.50 0.43 0.44 0.40 0.58 
 count cell lines  60 59 60 60 57 60 59 59 58 
 seed stdDev  0.82 0.83 0.82 0.82 0.83 0.82 0.76 0.83 0.84 
 target stdDev  0.82 0.52 0.89 0.57 1.04 0.76 0.58 1.28 0.87 
186052 
NSC:S756016 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
15 0.81 1.00 0.66 0.73 0.50 0.48 0.33 0.43 0.53 
 count cell lines  59 59 59 59 56 59 58 58 57 
 seed stdDev  0.52 0.52 0.52 0.52 0.53 0.52 0.53 0.53 0.53 
 target stdDev  0.83 0.52 0.84 0.56 1.04 0.76 0.51 1.28 0.87 
1685 
NSC:S756013 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
16 0.84 0.66 1.00 0.86 0.53 0.42 0.62 0.31 0.40 
 count cell lines  60 59 60 60 57 60 59 59 58 
 seed stdDev  0.89 0.84 0.89 0.89 0.90 0.89 0.84 0.89 0.90 
 target stdDev  0.82 0.52 0.89 0.57 1.04 0.76 0.58 1.28 0.87 
367298 
NSC:S756014 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
17 0.79 0.73 0.87 1.00 0.52 0.45 0.45 0.31 0.38 
 count cell lines  60 59 60 60 57 60 59 59 58 
 seed stdDev  0.57 0.56 0.57 0.57 0.58 0.57 0.56 0.58 0.57 
 target stdDev  0.82 0.52 0.89 0.57 1.04 0.76 0.58 1.28 0.87 
323413 
NSC:S757 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
2 0.50 0.50 0.53 0.52 1.00 0.75 0.22 0.51 0.49 
 count cell lines  57 56 57 57 68 67 56 68 66 
 seed stdDev  1.04 1.04 1.04 1.04 1.06 1.06 1.04 1.06 1.07 
 target stdDev  0.83 0.53 0.90 0.58 1.06 0.83 0.58 1.30 0.95 
90731 
NSC:S51046 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
3 0.43 0.48 0.42 0.45 0.74 1.00 0.02 0.71 0.58 
 count cell lines  60 59 60 60 67 70 59 69 67 
 seed stdDev  0.76 0.76 0.76 0.76 0.83 0.82 0.76 0.82 0.81 
 target stdDev  0.82 0.52 0.89 0.57 1.06 0.82 0.58 1.30 0.96 
323481 
NSC:S51045 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
4 0.44 0.33 0.62 0.45 0.22 0.02 1.00 -0.01 0.12 
 count cell lines  59 58 59 59 56 59 59 58 57 
 seed stdDev  0.58 0.51 0.58 0.58 0.58 0.58 0.58 0.59 0.59 
 target stdDev  0.76 0.53 0.84 0.56 1.04 0.76 0.58 1.29 0.87 
148899 
NSC:S613729 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-5.0 
6 0.40 0.43 0.31 0.31 0.51 0.71 -0.01 1.00 0.77 
 count cell lines  59 58 59 59 68 69 58 70 68 
 seed stdDev  1.28 1.28 1.28 1.28 1.30 1.30 1.29 1.29 1.25 
 target stdDev  0.83 0.53 0.89 0.57 1.06 0.82 0.59 1.29 0.95 
98121 
NSC:S645646 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-6.0 
7 0.58 0.53 0.40 0.38 0.49 0.58 0.12 0.77 1.00 
 count cell lines  58 57 58 58 66 67 57 68 68 
 seed stdDev  0.87 0.87 0.87 0.87 0.95 0.96 0.87 0.95 0.95 
 target stdDev  0.84 0.53 0.90 0.57 1.07 0.81 0.59 1.25 0.95 
 9 
(ii) Using the standard COMPARE protocol, the antiproliferative activity profiles of 
the 1 and 15–17 were compared with those of the NCI standard agents collection of 
anticancer agents.  The analysis was also carried out with 2–4, 6 and 7 as the seeds.  
The results, shown below, provided the source data for Table 3c. 
 
r 
value Seed Target Seed vector identity 
Target vector 
identity 
Count 
common 
cell lines 
Seed 
standard 
deviation 
Target 
standard 
deviation 
0.567 1 vincristine sulfate NSC:S756015 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S67574 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-3.0 
59 0.829 0.648 
0.508 1 paclitaxel (Taxol) NSC:S756015 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S125973 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
60 0.822 0.673 
0.507 1 maytansine NSC:S756015 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S153858 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-3.6 
47 0.749 0.674 
0.502 1 glycoxalic acid NSC:S756015 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S267213 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-2.9 
58 0.821 0.213 
0.450 1 tiazofurin NSC:S756015 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S286193 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-2.0 
58 0.821 0.727 
0.444 1 vincristine sulfate NSC:S756015 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S67574 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-5.0 
59 0.829 0.964 
0.444 1 maytansine NSC:S756015 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S153858 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-8.6 
41 0.776 1.592 
0.431 1 vinblastine sulfate NSC:S756015 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S49842 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-5.6 
60 0.822 0.843 
0.429 1 rhizoxin NSC:S756015 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S332598 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.3 
47 0.749 0.837 
0.426 1 soluble Baker's 
Antifol 
NSC:S756015 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S139105 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
57 0.828 1.499 
0.419 1 AT-125 (acivicin) NSC:S756015 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S163501 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
54 0.784 0.436 
0.416 1 DHAD 
(mitoxantrone) 
NSC:S756015 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S301739 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.6 
58 0.821 0.696 
0.416 1 maytansine NSC:S756015 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S153858 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-7.0 
58 0.832 0.720 
0.409 1 CCNU NSC:S756015 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S79037 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-3.3 
58 0.792 0.504 
0.401 1 paclitaxel (Taxol) NSC:S756015 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S125973 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-6.0 
60 0.822 0.533 
0.400 1 largomycin NSC:S756015 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S237020 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:2.6 
59 0.829 0.322 
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0.621 15 vincristine sulfate NSC:S756016 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S67574 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-3.0 
58 0.528 0.653 
0.558 15 maytansine NSC:S756016 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S153858 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-3.6 
46 0.469 0.681 
0.535 15 maytansine NSC:S756016 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S153858 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
58 0.528 0.691 
0.502 15 vinblastine sulfate NSC:S756016 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S49842 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-5.6 
59 0.524 0.850 
0.492 15 MX2 HCl NSC:S756016 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S619003 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
46 0.469 0.469 
0.475 15 vinblastine sulfate NSC:S756016 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S49842 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
56 0.495 0.587 
0.470 15 tiazofurin NSC:S756016 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S286193 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-2.0 
57 0.512 0.734 
0.462 15 maytansine NSC:S756016 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S153858 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-7.0 
57 0.512 0.708 
0.453 15 rhizoxin NSC:S756016 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S332598 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.3 
46 0.469 0.837 
0.448 15 paclitaxel (Taxol) NSC:S756016 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S125973 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-6.0 
59 0.524 0.531 
0.445 15 DON NSC:S756016 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S7365 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-3.6 
56 0.489 0.520 
0.444 15 vincristine sulfate NSC:S756016 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S67574 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-5.0 
58 0.528 0.971 
0.441 15 AT-125 (acivicin) NSC:S756016 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S163501 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
53 0.541 0.428 
0.440 15 paclitaxel (Taxol) NSC:S756016 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S125973 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.6 
59 0.524 0.646 
0.435 15 S-trityl-L-cysteine NSC:S756016 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S83265 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
46 0.472 0.601 
0.433 15 bispyridocarbazolium 
DMS 
NSC:S756016 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S366241 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
44 0.472 0.756 
0.432 15 methotrexate NSC:S756016 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S740 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-3.6 
59 0.524 1.150 
0.429 15 menogaril NSC:S756016 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S269148 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-5.0 
49 0.490 0.497 
0.427 15 PALA NSC:S756016 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S224131 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-2.0 
57 0.512 0.727 
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0.423 15 DHAD 
(mitoxantrone) 
NSC:S756016 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S301739 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.6 
57 0.512 0.698 
0.423 15 soluble Baker's 
Antifol 
NSC:S756016 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S139105 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
56 0.516 1.491 
0.410 15 m-AMSA 
(amsacrine) 
NSC:S756016 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S249992 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
49 0.490 0.752 
0.409 15 m-AMSA 
(amsacrine) 
NSC:S756016 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S249992 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-3.8 
45 0.483 0.814 
0.405 15 soluble Baker's 
Antifol 
NSC:S756016 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S139105 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-3.0 
57 0.512 1.297 
0.402 15 pyrazoloacridine NSC:S756016 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S366140 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-3.2 
58 0.528 0.295 
0.401 15 CCNU NSC:S756016 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S79037 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-3.3 
57 0.488 0.508 
0.400 15 methotrexate NSC:S756016 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S740 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-5.0 
55 0.494 1.020 
0.539 16 maytansine NSC:S756013 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S153858 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-7.0 
58 0.892 0.720 
0.531 16 vincristine sulfate NSC:S756013 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S67574 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-5.0 
59 0.889 0.964 
0.528 16 vincristine sulfate NSC:S756013 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S67574 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-3.0 
59 0.889 0.648 
0.488 16 paclitaxel (Taxol) NSC:S756013 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S125973 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
60 0.890 0.673 
0.467 16 vinblastine sulfate NSC:S756013 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S49842 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-5.6 
60 0.890 0.843 
0.464 16 soluble Baker's 
Antifol 
NSC:S756013 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S139105 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
57 0.890 1.499 
0.462 16 cyanomorpholino-
ADR 
NSC:S756013 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S357704 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-7.7 
59 0.889 0.412 
0.445 16 rhizoxin NSC:S756013 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S332598 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.3 
47 0.820 0.837 
0.443 16 hydrazine sulfate NSC:S756013 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S150014 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-2.5 
57 0.890 0.383 
0.440 16 paclitaxel (Taxol) NSC:S756013 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S125973 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.6 
60 0.890 0.653 
0.439 16 AT-125 (acivicin) NSC:S756013 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S163501 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
54 0.862 0.436 
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0.437 16 paclitaxel (Taxol) NSC:S756013 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S125973 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-6.0 
60 0.890 0.533 
0.429 16 DUP785 (brequinar) NSC:S756013 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S368390 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-2.3 
57 0.890 0.955 
0.417 16 tiazofurin NSC:S756013 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S286193 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-2.0 
58 0.883 0.727 
0.413 16 maytansine NSC:S756013 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S153858 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-3.6 
47 0.820 0.674 
0.404 16 maytansine NSC:S756013 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S153858 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-8.6 
41 0.859 1.592 
0.402 16 methotrexate NSC:S756013 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S740 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-3.6 
60 0.890 1.150 
0.599 17 paclitaxel (Taxol) NSC:S756014 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S125973 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
60 0.568 0.673 
0.563 17 maytansine NSC:S756014 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S153858 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-7.0 
58 0.570 0.720 
0.559 17 vincristine sulfate NSC:S756014 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S67574 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-3.0 
59 0.567 0.648 
0.520 17 rhizoxin NSC:S756014 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S332598 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.3 
47 0.507 0.837 
0.499 17 vincristine sulfate NSC:S756014 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S67574 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-5.0 
59 0.567 0.964 
0.498 17 paclitaxel (Taxol) NSC:S756014 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S125973 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.6 
60 0.568 0.653 
0.479 17 vinblastine sulfate NSC:S756014 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S49842 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-5.6 
60 0.568 0.843 
0.473 17 paclitaxel (Taxol) NSC:S756014 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S125973 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-6.0 
60 0.568 0.533 
0.472 17 soluble Baker's 
Antifol 
NSC:S756014 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S139105 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
57 0.557 1.499 
0.468 17 vinblastine sulfate NSC:S756014 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S49842 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
57 0.463 0.583 
0.427 17 maytansine NSC:S756014 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S153858 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-8.6 
41 0.528 1.592 
0.421 17 hydrazine sulfate NSC:S756014 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S150014 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-2.5 
57 0.557 0.383 
0.419 17 trimetrexate NSC:S756014 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S352122 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-6.0 
53 0.557 1.448 
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0.418 17 paclitaxel (Taxol) NSC:S756014 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S125973 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-5.0 
60 0.568 0.652 
0.416 17 DUP785 (brequinar) NSC:S756014 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S368390 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-2.3 
57 0.557 0.955 
0.415 17 maytansine NSC:S756014 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S153858 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
59 0.567 0.687 
0.408 17 methotrexate NSC:S756014 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S740 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-3.6 
60 0.568 1.150 
0.406 17 maytansine NSC:S756014 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S153858 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-3.6 
47 0.507 0.674 
0.404 17 methotrexate NSC:S756014 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S740 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-5.0 
56 0.541 1.036 
0.784 2 vincristine sulfate NSC:S757 Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
 
NSC:S67574 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-3.0 
68 1.055 0.654 
0.750 2 vinblastine sulfate NSC:S757 Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S49842 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-5.6 
68 1.055 0.836 
0.738 2 rhizoxin NSC:S757 Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S332598 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.3 
54 0.92 0.933 
0.546 2 pancratistatin NSC:S757 Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S349156 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-6.0 
49 1.021 0.135 
0.543 2 paclitaxel (Taxol) NSC:S757 Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S125973 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.6 
66 1.067 0.594 
0.758 2 maytansine NSC:S757 Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S153858 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-9.0 
54 0.92 0.96 
0.806 3 vincristine sulfate NSC:S51046 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S67574 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-3.0 
69 0.823 0.651 
0.886 3 vinblastine sulfate NSC:S51046 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S49842 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
58 0.716 0.578 
0.826 3 rhizoxin NSC:S51046 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S332598 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
68 0.721 0.464 
0.400 3 pancratistatin NSC:S51046 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S349156 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-6.0 
49 0.791 0.135 
0.360 3 paclitaxel (Taxol) NSC:S51046 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S125973 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.6 
68 0.827 0.653 
0.873 3 maytansine NSC:S51046 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S153858 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
69 0.823 0.693 
0.405 4 vincristine sulfate NSC:S51045 
Endpt:GI50 
ExpId:AVGDATA 
NSC:S67574 
Endpt:GI50 
ExpId:AVGDATA 
58 0.586 0.97 
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hiConc:-4.0 hiConc:-5.0 
0.286 4 vinblastine sulfate NSC:S51045 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S49842 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-7.6 
46 0.64 0.77 
0.378 4 rhizoxin NSC:S51045 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S332598 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.3 
46 0.641 0.843 
0.494 4 paclitaxel (Taxol) NSC:S51045 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S125973 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.6 
59 0.584 0.658 
0.468 4 maytansine NSC:S51045 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
NSC:S153858 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-3.6 
46 0.641 0.68 
0.577 6 vincristine sulfate NSC:S613729 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-5.0 
NSC:S67574 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-3.0 
70 1.292 0.647 
0.643 6 vinblastine sulfate NSC:S613729 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-5.0 
NSC:S49842 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
58 1.239 0.578 
0.635 6 rhizoxin NSC:S613729 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-5.0 
NSC:S332598 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-9.0 
65 1.206 0.714 
0.541 6 pancratistatin NSC:S613729 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-5.0 
NSC:S349156 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-6.0 
49 1.266 0.135 
0.674 6 maytansine NSC:S613729 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-5.0 
NSC:S153858 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
70 1.292 0.689 
0.382 6 actinomycin D NSC:S613729 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-5.0 
NSC:S3053 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-5.6 
62 1.222 0.518 
0.503 7 vincristine sulfate NSC:S645646 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-6.0 
NSC:S67574 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-3.0 
68 0.95 0.656 
0.439 7 vinblastine sulfate NSC:S645646 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-6.0 
NSC:S49842 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-5.6 
68 0.95 0.87 
0.585 7 rhizoxin NSC:S645646 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-6.0 
NSC:S332598 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
67 0.952 0.448 
0.593 7 pancratistatin NSC:S645646 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-6.0 
NSC:S349156 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-6.0 
48 0.969 0.136 
0.447 7 maytansine NSC:S645646 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-6.0 
NSC:S153858 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
68 0.95 0.67 
0.419 7 maytansine NSC:S645646 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-6.0 
NSC:S153858 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-3.6 
54 0.917 0.653 
0.465 7 pancratistatin NSC:S645646 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-6.0 
NSC:S349156 
Endpt:GI50 
ExpId:AVGDATA 
hiConc:-4.0 
68 0.95 0.621 
a Correlation (r) values are Pearson's correlation coefficients based on a comparison of the NCI GI50 
mean graphs for each compound.38 
  
 15 
Section 4.2.3.  In vivo antivascular effects of 15 
 
Results:  The amount of functional vascular elements (as determined by the 
incorporation of the Hoechst 33342 dye into the nuclei of functioning endothelial 
cells) was significantly affected by administration of both 15 and 21 in all animals 
examined 1 h after administration.  This persisted throughout the 24-h study period 
for 21, whereas for 15 recovery of vasculature was seen from 4 h post dose (Figure 1, 
Table 4.2.3.1, and the representative images in Figure 3).  Whilst there is a decrease 
again at 24 h for 15 from 4 h, it is not to the same extent as seen for 21 at 24 h 
compared with 4 h.  Histological evaluation of haematoxylin and eosin stained 
sections showed a notable increase in the amount of necrosis in the DLD-1 tumours at 
24 h post-administration for both compounds (Figure 2, Table 4.2.3.2, and the 
representative images in Figure 4). 
 
Conclusions 
Compound 15 is well tolerated when administered intravenously at 400 mg kg–1 in a 
multiple-dose schedule. Both 15 and 21 induce vascular shutdown 1 h after treatment 
when administered as a single intravenous dose of 400 mg kg–1, with tumour necrosis 
evident after 24 h. 
 
Table 4.2.3.1  Summary of % vascular element counts seen in DLD-1 human colon 
adenocarcinoma xenografts following a single intravenous dose of 15 or 21 at 
400 mg kg–1 (data used for Figure 1). 
 
 % vascular element counts 
  15 21 
 Untreated 1 h post-dose 
4 h post-
dose 
24 h post-
dose 
1 h post-
dose 
4 h post-
dose 
24 h post-
dose 
Tumour 1 7.30 0.55 1.35 1.80 0.00 0.08 1.06 
Tumour 2 2.20 0.41 1.52 0.91 0.02 0.22 0.10 
Tumour 3 1.70 0.04 3.02 0.14 0.07 0.06 0.10 
Mean ± SD 3.73 ± 3.10 0.33 ± 0.26 
1.96 ± 
0.92 
0.95 ± 
0.83 
0.03 ± 
0.06 
0.12 ± 
0.09 
0.42 ± 
0.55 
 
Table 4.2.3.2  Summary of % necrotic area counts seen in DLD-1 human colon 
adenocarcinoma xenografts following a single intravenous dose of 15 or 21 at 
400 mg kg–1 (data used for Figure 2) 
 
 % necrotic area counts 
  15 21 
 Untreated 1 h post-dose 
4 h post-
dose 
24 h post-
dose 
1 h post-
dose 
4 h post-
dose 
24 h post-
dose 
Tumour 1 8.5 33.3 24.1 73.6 28.5 18.9 78.3 
Tumour 2 27.4 39.6 29.0 97.5 39.5 39.3 98.6 
Tumour 3 21.2 8.4 24.9 51.1 1.6 8.6 96.2 
Mean ± SD 19.0 ± 9.6 27.1 ± 16.5 26.0 ± 2.6 
74.1 ± 
23.2 
23.2 ± 
19.5 
22.3 ± 
15.6 
91.0 ± 
11.1 
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Section 4.2.5.  Dynamic 3D-solution structure of 1 
The methodology of Blundell et al.51 was used to analyse the conformational 
dynamics of dibenzoxepine 1 in dilute aqueous solution, as described below. 
 
(i) Data acquisition 
Solutions of 1 (1.0 mM) in 2% (v/v) d6-DMSO, 98% D2O at 25 ˚C (0.3 mM d6-DSS 
internal reference) were analysed by NMR spectroscopy (Bruker DRX-600, Topspin 
1.3; 1H at 600 MHz, 13C at 151 MHz) using the [1H]-1D, [1H,13C]-HSQC, [1H,13C]-
HMBC and [1H,1H]-ROESY experiments.  Comparison of the [1H]-1D-NMR 
spectrum with that obtained with 0.05 mM 1 in 0.1% d6-DMSO, 99.9% (v/v) D2O at 
25 ˚C showed no significant chemical shift differences (<0.1 ppm) due to the increase 
in solute concentration, indicating that no aggregation or multimerisation was 
occurring in the range 0.05–1.0 mM.  It was concluded that the conformational 
properties of 1 at the higher concentration would be indistinguishable from those 
present under the more dilute conditions. 
 
(ii) Chemical shift assignments 
All of the 1H and 13C atoms in 1 were unambiguously assigned using [1H]-1D, 
[1H,13C]-HSQC and [1H,13C]-HMBC spectra (Table 4.2.5.1).  Broadened resonances 
observed in the [1H]-1D spectra, assigned to H51, H52, H71 and H72, indicated that 
the oxepane ring exists as a mixture of two atropisomers (necessarily 50:50).  
 
Table 4.2.5.1.  Chemical shifts for 1. 
 
Atoma δC / 
ppmb 
Atoma δH / ppmc 
C1 123.825 H1 7.203 
C2 114.924 H2 7.179 
C3 149.865 H3 3.950 
C3M 58.910 HO4 n/a 
C4 146.038 H51/52d 5.096/3.827 
C4A 124.080 H71/72d 4.491/3.987 
C5 61.801 H8 7.035 
C7 69.613 H9 3.943 
C7A 133.669 H10 3.917 
C8 112.386 H11 3.646 
C9 155.300   
C9M 58.852   
C10 144.658   
C10M 64.014   
C11 152.330   
C11M 63.763   
C11A 129.112   
C11B 132.743   
 
 
 
 
 
 
 
 
 
 
 
 
 
aRefer to Figure 4.2.5.1 for atom designations. 
bStd. error ±0.020 ppm.  
cStd. error ±0.001 ppm.  
dWhile the upfield-shifted resonance is clearly 
from the proton lying in the face of the 
adjacent aromatic ring, these protons cannot be 
individually assigned because the central 
oxepane ring is in intermediate exchange 
between two atropoisomers; in one form the 
pro-R proton is in the face of aromatic ring, 
while in the other it is the pro-S proton. 
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Figure 4.2.5.1.  Numbering system used for 1.  Degenerate hydrogen nuclei in methyl 
groups are indicated with an asterisk. 
 
(iii) Dynamic 3D-structure of 1 
The molecule 1 has five single bonds with geometry that is not predetermined by local 
orbitals, and whose conformations affect the overall 3D-shape of the molecule.  In 
addition, the oxepane ring can adopt alternative puckered conformations that are 
rigidly defined (the broadened resonances seen for H51, H52, H71 and H72 indicates 
that these two ring conformations are atropoisomers).  The molecule thus incorporates 
six degrees of freedom (Figure 4.2.5.2 and Table 4.2.5.2). 
 
 
Figure 4.2.5.2.  Molecular degrees of freedom within 1 that affect the conformation 
of the molecule.  Each degree of freedom is defined as shown in Table 4.2.5.2. 
 
Table 4.2.5.2.  Definitions of molecular degrees of freedom in 1. 
 
Degree of freedoma Atoms defining ring puckering 
1 C4A-C5-O6-C7-C11A-C11B dihedral reported for: C7A-C11A-C11B-C4A 
 Atoms defining rotatable bond dihedral angles 
2 C2-C3-O3-C3M 
3 C3-C4-O4-HO4 
4 C8-C9-O9-C9M 
5 C9-C10-O10-C10M 
6 C10-C11-O11-C11M 
aDegree of freedom numbers are as defined in Figure 4.2.5.2. 
O
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6
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In total, 29 experimentally-determined structural restraints were used to assess the 
dynamic 3D-structure of 1.  Since the two atropisomers have a geometry defined by 
the local chemical bonds, there were therefore only 5 unknown degrees of freedom, 
giving a mean value of 5.8 restraints per unknown degree of freedom.  
 
(iv) Conformetrics51 
The results of the analysis of the dynamic 3D-structure of 1 in aqueous solution are 
given in Table 4.2.5.3.  The number of conformers adopted by each rotatable bond 
and their relative occupancies were determined.  For each adopted conformer, its 
mean dihedral angle and librational amplitude was measured.  Notes on the behaviour 
of each bond are provided below. 
 
Table 4.2.5.3. Experimentally-determined conformetrics for 1 in aqueous solution. 
 
Degree of 
freedom no.a Conformation
b Mean angle / 
pucker conformation Occupancy
c 
1 1 
2 
45˚ 
–45˚ 
 0.50 
0.50 
2 1 
2 
136 ± 4˚ 
–136 ± 4˚ 
 0.50 
0.50 
3 1 
2 
108 ± 20˚ 
–108 ± 20˚ 
 0.50 
0.50 
4 1 
2 
139 ± 5˚ 
–139 ± 5˚ 
 0.50 
0.50 
5 1 
2 
142 ± 20˚ 
–142 ± 20˚ 
 0.50 
0.50 
6 1 (1-1)e 
2 (1-2)e 
78 ± 3˚ 
–78 ± 3˚ 
 0.50 
0.50 
aDegrees of freedom and their associated dihedral angles are as defined in Figure 4.2.5.2 and 
Table 4.2.5.2. 
bConformers are classified as distinct if rotation of the bond between the two conformers 
passes through a van der Waals maximum. 
cThe occupancy of each conformer is expressed as a proportion of the total for that bond. 
dThe conformation of bond 6 depends upon the oxepane ring conformation. 
 
• Oxepane ring conformation:  This ring is in intermediate exchange between two 
symmetric atropisomers.  The dihedral angle is that for C4A-C11B-C11A-C7A. 
• Bonds 2, 4, 5:  Each methoxyl group can adopt two symmetrical conformers that 
are independent of the oxepane ring conformation and each other. 
• Bond 3:  The dihedral angle for the hydroxyl is poorly defined because the 4OH 
proton is not directly observable in aqueous solution.  However, it clearly adopts 
two symmetrical conformers about the adjacent aromatic and oxepane rings. 
• Bond 6:  The conformation of this bond depends on the oxepane conformation, 
preferring a particular orientation for each alternative conformer.  
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(v) Conformers 
Using the data from Table 4.2.5.3, it is possible to calculate the number of distinct 
conformers in aqueous solution that 1 naturally explores; within each of these the 
molecule will be seen to be librating.  As shown in Table 4.2.5.3 and Figure 4.2.5.3, 
the dynamic 3D-structure of 1 can be considered to be a set of 32 distinct conformers, 
which is arrived at by the simple permutation of all the independent conformers for 
each bond/degree of freedom. The occupancies of these conformers are calculated to 
be equal.  The conformational preference of bond 6 is linked to the oxepane 
conformation: C5 and C11M tend to be proximal. 
 
 
Figure 4.2.5.3.  Idealised conformers adopted by 1 in aqueous solution, overlaid on 
atoms C11A, C8 and C10.  Top: all 32 idealised conformers.  Bottom: these 32 
conformers can be classified into two pseudo-symmetrical sets of 16 conformers each 
according to the oxepane ring pucker.  C atoms are shown in grey and O in red; H 
atoms have been omitted for clarity. 
 
(vi) Conformational libration of 1 
The aqueous solution structure of 1 can represented by an ensemble of 3D-structures 
in which the distribution of conformations accurately reflects the measured 
conformetrics listed in Table 4.2.5.3.  This ensemble reveals conformations explored 
away from the mean values via librational motions.  The ensemble representation of 1 
is shown in Figure 5a. 
 
*
*
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(vii) Overlay of 1 with DAMA-colchicine (Figure 5b) 
The DAMA-colchicine:αβ-tubulin:RB3 (1SA0) crystal structure20a contains two 
molecules of DAMA-colchicine 38, identified as residues [CN2]700 and [CN2]701, 
each located within a β-subunit at the αβ-interface of a tubulin heterodimer.  
Comparative models with 1 bound in each of these sites in place of 38 were generated 
using PyMOL.60  Figure 5b shows the closest matching preferred solution conformer 
of 1 fitted to the [CN2]701 site superimposed on the colchicinoid [CN2]701 itself, 
with alignment on the conserved atoms of the respective trimethoxyaryl rings.  It is 
noted that both of the bound conformations of 38 are implausible, the tropolone rings 
having incorrect bond lengths and angles.  Upon minimisation, O3 moves by 1.3 Å, 
O4 by 1.0 Å and C3M by 1.9 Å.  These deviations are not trivial and suggest that the 
bound conformation of DAMA-colchicine 38 in 1SA0 retains some ring puckering 
and flexibility in the bound state. 
 
(viii) Overlay of 1 and 6 with colchicine 3 (Figure 5c) 
The conformation of combretastatin A-4 6 bound to the [CN2]700 site of 1SA0 was 
modelled and is shown in Figure 5c as an overlay, together with 1, on the crystal 
structure of colchicine 3,52 with alignment of the respective trimethoxyaryl rings.  
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